[
  {
    "id":1,
    "pmid":40275823,
    "title":"Anaphylactic Reaction to Lisinopril: Case Report and Literature Review",
    "abstract":"We describe a case of anaphylactic reaction in a 38-year-old male (patient code: ANP-2025-087) following intravenous administration of Lisinopril 50mg. The reaction occurred within 15 minutes of drug administration and was managed by Dr. Emily Rodriguez in the emergency department. The patient developed urticaria, bronchospasm, and hypotension (BP 80\/50 mmHg). Treatment with epinephrine, corticosteroids, and antihistamines resulted in complete recovery. This case highlights the importance of monitoring for hypersensitivity reactions.",
    "authors":"Smith R; Rodriguez W",
    "first_author":"Smith R",
    "journal":"British Journal of Clinical Pharmacology",
    "publication_year":2025,
    "create_date":"2025-12-11",
    "pmcid":"PMC1005321",
    "doi":"10.5434\/sef9t5m0xg",
    "citation":"Smith R et al. British Journal of Clinical Pharmacology. 2025;103(5):246-207.",
    "product_inn":"Lisinopril",
    "product_id":3,
    "category":"icsr_cannot_exclude",
    "adverse_events":[
      "Anaphylaxis",
      "Urticaria",
      "Bronchospasm",
      "Hypotension"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":false,
    "exclusion_reason":null,
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":2,
    "pmid":40029430,
    "title":"Anaphylactic Reaction to Doxorubicin: Case Report and Literature Review",
    "abstract":"We describe a case of anaphylactic reaction in a 38-year-old male (patient code: ANP-2025-087) following intravenous administration of Doxorubicin 50mg. The reaction occurred within 15 minutes of drug administration and was managed by Dr. Emily Rodriguez in the emergency department. The patient developed urticaria, bronchospasm, and hypotension (BP 80\/50 mmHg). Treatment with epinephrine, corticosteroids, and antihistamines resulted in complete recovery. This case highlights the importance of monitoring for hypersensitivity reactions.",
    "authors":"Jones S; Davis E; Williams E; Davis W",
    "first_author":"Jones S",
    "journal":"European Journal of Clinical Pharmacology",
    "publication_year":2024,
    "create_date":"2024-11-22",
    "pmcid":"",
    "doi":"10.6841\/gxsdlbbgf3",
    "citation":"Jones S et al. European Journal of Clinical Pharmacology. 2024;95(2):347-811.",
    "product_inn":"Doxorubicin",
    "product_id":10,
    "category":"icsr_cannot_exclude",
    "adverse_events":[
      "Anaphylaxis",
      "Urticaria",
      "Bronchospasm",
      "Hypotension"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":false,
    "exclusion_reason":null,
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":3,
    "pmid":40494649,
    "title":"Anaphylactic Reaction to Simvastatin: Case Report and Literature Review",
    "abstract":"We describe a case of anaphylactic reaction in a 38-year-old male (patient code: ANP-2025-087) following intravenous administration of Simvastatin 50mg. The reaction occurred within 15 minutes of drug administration and was managed by Dr. Emily Rodriguez in the emergency department. The patient developed urticaria, bronchospasm, and hypotension (BP 80\/50 mmHg). Treatment with epinephrine, corticosteroids, and antihistamines resulted in complete recovery. This case highlights the importance of monitoring for hypersensitivity reactions.",
    "authors":"Rodriguez J; Martinez L; Rodriguez E; Williams J",
    "first_author":"Rodriguez J",
    "journal":"BMC Pharmacology and Toxicology",
    "publication_year":2025,
    "create_date":"2025-12-24",
    "pmcid":"PMC1894334",
    "doi":"10.7784\/cfwu7w54r5",
    "citation":"Rodriguez J et al. BMC Pharmacology and Toxicology. 2025;33(10):998-579.",
    "product_inn":"Simvastatin",
    "product_id":5,
    "category":"icsr_cannot_exclude",
    "adverse_events":[
      "Anaphylaxis",
      "Urticaria",
      "Bronchospasm",
      "Hypotension"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":false,
    "exclusion_reason":null,
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":4,
    "pmid":40565296,
    "title":"Anaphylactic Reaction to Doxorubicin: Case Report and Literature Review",
    "abstract":"We describe a case of anaphylactic reaction in a 38-year-old male (patient code: ANP-2025-087) following intravenous administration of Doxorubicin 50mg. The reaction occurred within 15 minutes of drug administration and was managed by Dr. Emily Rodriguez in the emergency department. The patient developed urticaria, bronchospasm, and hypotension (BP 80\/50 mmHg). Treatment with epinephrine, corticosteroids, and antihistamines resulted in complete recovery. This case highlights the importance of monitoring for hypersensitivity reactions.",
    "authors":"Brown W; Garcia R; Johnson M; Johnson M; Williams M; Jones S",
    "first_author":"Brown W",
    "journal":"Journal of Medical Case Reports",
    "publication_year":2024,
    "create_date":"2024-07-14",
    "pmcid":"",
    "doi":"10.8060\/y87vqq54nf",
    "citation":"Brown W et al. Journal of Medical Case Reports. 2024;93(4):231-334.",
    "product_inn":"Doxorubicin",
    "product_id":10,
    "category":"icsr_cannot_exclude",
    "adverse_events":[
      "Anaphylaxis",
      "Urticaria",
      "Bronchospasm",
      "Hypotension"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":false,
    "exclusion_reason":null,
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":5,
    "pmid":40579929,
    "title":"Severe Hepatotoxicity Following Atorvastatin Administration in a 45-Year-Old Male Patient",
    "abstract":"We report a case of a 45-year-old male patient (initials J.M.) who developed severe hepatotoxicity after receiving Atorvastatin 20mg oral. The patient was treated by Dr. Sarah Johnson at Memorial Hospital. Laboratory findings showed elevated liver enzymes (ALT 450 U\/L, AST 380 U\/L) three days after initiation of therapy. The adverse event was reported to the hospital's pharmacovigilance department. The patient recovered after discontinuation of Atorvastatin and supportive care.",
    "authors":"Brown M; Martinez W; Jones L",
    "first_author":"Brown M",
    "journal":"Journal of Medical Case Reports",
    "publication_year":2025,
    "create_date":"2025-06-16",
    "pmcid":"PMC9506178",
    "doi":"10.2963\/6lu5ycqw32",
    "citation":"Brown M et al. Journal of Medical Case Reports. 2025;52(10):393-956.",
    "product_inn":"Atorvastatin",
    "product_id":14,
    "category":"icsr_cannot_exclude",
    "adverse_events":[
      "Hepatotoxicity",
      "Elevated liver enzymes"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":false,
    "exclusion_reason":null,
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":6,
    "pmid":40334105,
    "title":"Severe Hepatotoxicity Following Metronidazole Administration in a 45-Year-Old Male Patient",
    "abstract":"We report a case of a 45-year-old male patient (initials J.M.) who developed severe hepatotoxicity after receiving Metronidazole as prescribed oral. The patient was treated by Dr. Sarah Johnson at Memorial Hospital. Laboratory findings showed elevated liver enzymes (ALT 450 U\/L, AST 380 U\/L) three days after initiation of therapy. The adverse event was reported to the hospital's pharmacovigilance department. The patient recovered after discontinuation of Metronidazole and supportive care.",
    "authors":"Johnson M; Davis M; Miller J; Miller E; Garcia M; Brown M",
    "first_author":"Johnson M",
    "journal":"Journal of Medical Case Reports",
    "publication_year":2024,
    "create_date":"2024-11-28",
    "pmcid":"",
    "doi":"10.4297\/2bxqgeirub",
    "citation":"Johnson M et al. Journal of Medical Case Reports. 2024;80(7):263-908.",
    "product_inn":"Metronidazole",
    "product_id":9,
    "category":"icsr_cannot_exclude",
    "adverse_events":[
      "Hepatotoxicity",
      "Elevated liver enzymes"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":false,
    "exclusion_reason":null,
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":7,
    "pmid":40885653,
    "title":"Acute Kidney Injury Associated with Insulin Glargine in Elderly Patient: A Case Report",
    "abstract":"A 72-year-old female patient (ID: 2024-PV-1234) presented with acute kidney injury following treatment with Insulin Glargine 50mg subcutaneous. The case was documented by Dr. Michael Chen, nephrologist at City General Hospital. Serum creatinine increased from 1.2 mg\/dL to 3.8 mg\/dL within 48 hours of drug administration. The patient required temporary dialysis. This adverse drug reaction was classified as serious and reported to regulatory authorities.",
    "authors":"Davis E; Smith S; Brown D; Jones M; Johnson L; Brown D",
    "first_author":"Davis E",
    "journal":"Journal of Clinical Pharmacology",
    "publication_year":2024,
    "create_date":"2024-06-26",
    "pmcid":"PMC5313319",
    "doi":"10.5862\/jfsgcqw8s4",
    "citation":"Davis E et al. Journal of Clinical Pharmacology. 2024;72(11):429-251.",
    "product_inn":"Insulin Glargine",
    "product_id":12,
    "category":"icsr_cannot_exclude",
    "adverse_events":[
      "Acute kidney injury",
      "Elevated serum creatinine"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":false,
    "exclusion_reason":null,
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":8,
    "pmid":40037427,
    "title":"Acute Kidney Injury Associated with Amlodipine in Elderly Patient: A Case Report",
    "abstract":"A 72-year-old female patient (ID: 2024-PV-1234) presented with acute kidney injury following treatment with Amlodipine 5mg oral. The case was documented by Dr. Michael Chen, nephrologist at City General Hospital. Serum creatinine increased from 1.2 mg\/dL to 3.8 mg\/dL within 48 hours of drug administration. The patient required temporary dialysis. This adverse drug reaction was classified as serious and reported to regulatory authorities.",
    "authors":"Martinez R; Williams S; Williams J; Garcia J; Brown D; Smith W",
    "first_author":"Martinez R",
    "journal":"Internal Medicine",
    "publication_year":2025,
    "create_date":"2025-04-10",
    "pmcid":"PMC8876644",
    "doi":"10.2739\/9m8s6lpast",
    "citation":"Martinez R et al. Internal Medicine. 2025;57(10):345-754.",
    "product_inn":"Amlodipine",
    "product_id":1,
    "category":"icsr_cannot_exclude",
    "adverse_events":[
      "Acute kidney injury",
      "Elevated serum creatinine"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":false,
    "exclusion_reason":null,
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":9,
    "pmid":40498169,
    "title":"Anaphylactic Reaction to Metformin: Case Report and Literature Review",
    "abstract":"We describe a case of anaphylactic reaction in a 38-year-old male (patient code: ANP-2025-087) following intravenous administration of Metformin 50mg. The reaction occurred within 15 minutes of drug administration and was managed by Dr. Emily Rodriguez in the emergency department. The patient developed urticaria, bronchospasm, and hypotension (BP 80\/50 mmHg). Treatment with epinephrine, corticosteroids, and antihistamines resulted in complete recovery. This case highlights the importance of monitoring for hypersensitivity reactions.",
    "authors":"Jones L; Garcia W; Johnson J",
    "first_author":"Jones L",
    "journal":"European Journal of Clinical Pharmacology",
    "publication_year":2025,
    "create_date":"2025-03-11",
    "pmcid":"",
    "doi":"10.4530\/nf7hyzr57m",
    "citation":"Jones L et al. European Journal of Clinical Pharmacology. 2025;71(9):817-643.",
    "product_inn":"Metformin",
    "product_id":2,
    "category":"icsr_cannot_exclude",
    "adverse_events":[
      "Anaphylaxis",
      "Urticaria",
      "Bronchospasm",
      "Hypotension"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":false,
    "exclusion_reason":null,
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":10,
    "pmid":40204333,
    "title":"Severe Hepatotoxicity Following Cisatracurium Administration in a 45-Year-Old Male Patient",
    "abstract":"We report a case of a 45-year-old male patient (initials J.M.) who developed severe hepatotoxicity after receiving Cisatracurium 1g intravenous. The patient was treated by Dr. Sarah Johnson at Memorial Hospital. Laboratory findings showed elevated liver enzymes (ALT 450 U\/L, AST 380 U\/L) three days after initiation of therapy. The adverse event was reported to the hospital's pharmacovigilance department. The patient recovered after discontinuation of Cisatracurium and supportive care.",
    "authors":"Smith J; Davis W",
    "first_author":"Smith J",
    "journal":"Internal Medicine",
    "publication_year":2025,
    "create_date":"2025-01-20",
    "pmcid":"PMC4675602",
    "doi":"10.7068\/h0er23wyln",
    "citation":"Smith J et al. Internal Medicine. 2025;130(10):797-583.",
    "product_inn":"Cisatracurium",
    "product_id":6,
    "category":"icsr_cannot_exclude",
    "adverse_events":[
      "Hepatotoxicity",
      "Elevated liver enzymes"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":false,
    "exclusion_reason":null,
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":11,
    "pmid":40595201,
    "title":"Severe Hepatotoxicity Following Atorvastatin Administration in a 45-Year-Old Male Patient",
    "abstract":"We report a case of a 45-year-old male patient (initials J.M.) who developed severe hepatotoxicity after receiving Atorvastatin 80mg oral. The patient was treated by Dr. Sarah Johnson at Memorial Hospital. Laboratory findings showed elevated liver enzymes (ALT 450 U\/L, AST 380 U\/L) three days after initiation of therapy. The adverse event was reported to the hospital's pharmacovigilance department. The patient recovered after discontinuation of Atorvastatin and supportive care.",
    "authors":"Williams L; Miller M; Smith W",
    "first_author":"Williams L",
    "journal":"British Journal of Clinical Pharmacology",
    "publication_year":2025,
    "create_date":"2025-12-27",
    "pmcid":"PMC1891700",
    "doi":"10.6535\/dzogtf6vaz",
    "citation":"Williams L et al. British Journal of Clinical Pharmacology. 2025;87(2):882-603.",
    "product_inn":"Atorvastatin",
    "product_id":14,
    "category":"icsr_cannot_exclude",
    "adverse_events":[
      "Hepatotoxicity",
      "Elevated liver enzymes"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":false,
    "exclusion_reason":null,
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":12,
    "pmid":40435738,
    "title":"Acute Kidney Injury Associated with Cisplatin in Elderly Patient: A Case Report",
    "abstract":"A 72-year-old female patient (ID: 2024-PV-1234) presented with acute kidney injury following treatment with Cisplatin 250mg intravenous. The case was documented by Dr. Michael Chen, nephrologist at City General Hospital. Serum creatinine increased from 1.2 mg\/dL to 3.8 mg\/dL within 48 hours of drug administration. The patient required temporary dialysis. This adverse drug reaction was classified as serious and reported to regulatory authorities.",
    "authors":"Smith M; Jones J; Davis M; Johnson D; Williams J",
    "first_author":"Smith M",
    "journal":"Drug Safety",
    "publication_year":2025,
    "create_date":"2025-12-11",
    "pmcid":"PMC7351628",
    "doi":"10.1847\/fc8zs3ucaw",
    "citation":"Smith M et al. Drug Safety. 2025;65(8):477-388.",
    "product_inn":"Cisplatin",
    "product_id":8,
    "category":"icsr_cannot_exclude",
    "adverse_events":[
      "Acute kidney injury",
      "Elevated serum creatinine"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":false,
    "exclusion_reason":null,
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":13,
    "pmid":40210225,
    "title":"Acute Kidney Injury Associated with Lisinopril in Elderly Patient: A Case Report",
    "abstract":"A 72-year-old female patient (ID: 2024-PV-1234) presented with acute kidney injury following treatment with Lisinopril 80mg oral. The case was documented by Dr. Michael Chen, nephrologist at City General Hospital. Serum creatinine increased from 1.2 mg\/dL to 3.8 mg\/dL within 48 hours of drug administration. The patient required temporary dialysis. This adverse drug reaction was classified as serious and reported to regulatory authorities.",
    "authors":"Miller M; Miller J; Jones L; Jones E; Miller M; Rodriguez M",
    "first_author":"Miller M",
    "journal":"Pharmacotherapy",
    "publication_year":2025,
    "create_date":"2025-05-14",
    "pmcid":"PMC4581872",
    "doi":"10.6145\/16bf1gs0b6",
    "citation":"Miller M et al. Pharmacotherapy. 2025;50(8):617-154.",
    "product_inn":"Lisinopril",
    "product_id":3,
    "category":"icsr_cannot_exclude",
    "adverse_events":[
      "Acute kidney injury",
      "Elevated serum creatinine"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":false,
    "exclusion_reason":null,
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":14,
    "pmid":40821468,
    "title":"Acute Kidney Injury Associated with Doxorubicin in Elderly Patient: A Case Report",
    "abstract":"A 72-year-old female patient (ID: 2024-PV-1234) presented with acute kidney injury following treatment with Doxorubicin 250mg intravenous. The case was documented by Dr. Michael Chen, nephrologist at City General Hospital. Serum creatinine increased from 1.2 mg\/dL to 3.8 mg\/dL within 48 hours of drug administration. The patient required temporary dialysis. This adverse drug reaction was classified as serious and reported to regulatory authorities.",
    "authors":"Davis S; Jones L; Williams W; Garcia E; Davis S; Smith M",
    "first_author":"Davis S",
    "journal":"Journal of Medical Case Reports",
    "publication_year":2024,
    "create_date":"2024-07-21",
    "pmcid":"PMC1448036",
    "doi":"10.5226\/eu5r805fp8",
    "citation":"Davis S et al. Journal of Medical Case Reports. 2024;87(1):873-740.",
    "product_inn":"Doxorubicin",
    "product_id":10,
    "category":"icsr_cannot_exclude",
    "adverse_events":[
      "Acute kidney injury",
      "Elevated serum creatinine"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":false,
    "exclusion_reason":null,
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":15,
    "pmid":40687016,
    "title":"Anaphylactic Reaction to Metformin: Case Report and Literature Review",
    "abstract":"We describe a case of anaphylactic reaction in a 38-year-old male (patient code: ANP-2025-087) following intravenous administration of Metformin 50mg. The reaction occurred within 15 minutes of drug administration and was managed by Dr. Emily Rodriguez in the emergency department. The patient developed urticaria, bronchospasm, and hypotension (BP 80\/50 mmHg). Treatment with epinephrine, corticosteroids, and antihistamines resulted in complete recovery. This case highlights the importance of monitoring for hypersensitivity reactions.",
    "authors":"Garcia S; Davis R; Brown L; Williams M; Garcia J",
    "first_author":"Garcia S",
    "journal":"British Journal of Clinical Pharmacology",
    "publication_year":2024,
    "create_date":"2024-08-17",
    "pmcid":"",
    "doi":"10.8833\/a18ntznto0",
    "citation":"Garcia S et al. British Journal of Clinical Pharmacology. 2024;86(10):758-336.",
    "product_inn":"Metformin",
    "product_id":2,
    "category":"icsr_cannot_exclude",
    "adverse_events":[
      "Anaphylaxis",
      "Urticaria",
      "Bronchospasm",
      "Hypotension"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":false,
    "exclusion_reason":null,
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":16,
    "pmid":40376488,
    "title":"Acute Kidney Injury Associated with Levothyroxine in Elderly Patient: A Case Report",
    "abstract":"A 72-year-old female patient (ID: 2024-PV-1234) presented with acute kidney injury following treatment with Levothyroxine 5mg oral. The case was documented by Dr. Michael Chen, nephrologist at City General Hospital. Serum creatinine increased from 1.2 mg\/dL to 3.8 mg\/dL within 48 hours of drug administration. The patient required temporary dialysis. This adverse drug reaction was classified as serious and reported to regulatory authorities.",
    "authors":"Davis R; Smith W; Smith R; Johnson E; Rodriguez L; Davis R",
    "first_author":"Davis R",
    "journal":"Pharmacotherapy",
    "publication_year":2024,
    "create_date":"2024-10-24",
    "pmcid":"",
    "doi":"10.9840\/pxs1mkpqxy",
    "citation":"Davis R et al. Pharmacotherapy. 2024;149(7):967-901.",
    "product_inn":"Levothyroxine",
    "product_id":13,
    "category":"icsr_cannot_exclude",
    "adverse_events":[
      "Acute kidney injury",
      "Elevated serum creatinine"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":false,
    "exclusion_reason":null,
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":17,
    "pmid":40659118,
    "title":"Acute Kidney Injury Associated with Doxorubicin in Elderly Patient: A Case Report",
    "abstract":"A 72-year-old female patient (ID: 2024-PV-1234) presented with acute kidney injury following treatment with Doxorubicin 100mg intravenous. The case was documented by Dr. Michael Chen, nephrologist at City General Hospital. Serum creatinine increased from 1.2 mg\/dL to 3.8 mg\/dL within 48 hours of drug administration. The patient required temporary dialysis. This adverse drug reaction was classified as serious and reported to regulatory authorities.",
    "authors":"Rodriguez D; Garcia L; Martinez R",
    "first_author":"Rodriguez D",
    "journal":"Journal of Clinical Pharmacology",
    "publication_year":2024,
    "create_date":"2024-06-10",
    "pmcid":"",
    "doi":"10.5447\/lykcy4pac9",
    "citation":"Rodriguez D et al. Journal of Clinical Pharmacology. 2024;114(3):685-112.",
    "product_inn":"Doxorubicin",
    "product_id":10,
    "category":"icsr_cannot_exclude",
    "adverse_events":[
      "Acute kidney injury",
      "Elevated serum creatinine"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":false,
    "exclusion_reason":null,
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":18,
    "pmid":40231553,
    "title":"Severe Hepatotoxicity Following Metronidazole Administration in a 45-Year-Old Male Patient",
    "abstract":"We report a case of a 45-year-old male patient (initials J.M.) who developed severe hepatotoxicity after receiving Metronidazole 1g oral. The patient was treated by Dr. Sarah Johnson at Memorial Hospital. Laboratory findings showed elevated liver enzymes (ALT 450 U\/L, AST 380 U\/L) three days after initiation of therapy. The adverse event was reported to the hospital's pharmacovigilance department. The patient recovered after discontinuation of Metronidazole and supportive care.",
    "authors":"Rodriguez S; Rodriguez E; Rodriguez J; Martinez M; Davis M; Rodriguez R",
    "first_author":"Rodriguez S",
    "journal":"Pharmacotherapy",
    "publication_year":2024,
    "create_date":"2024-09-06",
    "pmcid":"",
    "doi":"10.7572\/1zpi5lytm1",
    "citation":"Rodriguez S et al. Pharmacotherapy. 2024;81(11):145-680.",
    "product_inn":"Metronidazole",
    "product_id":9,
    "category":"icsr_cannot_exclude",
    "adverse_events":[
      "Hepatotoxicity",
      "Elevated liver enzymes"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":false,
    "exclusion_reason":null,
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":19,
    "pmid":40292746,
    "title":"Severe Hepatotoxicity Following Atorvastatin Administration in a 45-Year-Old Male Patient",
    "abstract":"We report a case of a 45-year-old male patient (initials J.M.) who developed severe hepatotoxicity after receiving Atorvastatin 5mg oral. The patient was treated by Dr. Sarah Johnson at Memorial Hospital. Laboratory findings showed elevated liver enzymes (ALT 450 U\/L, AST 380 U\/L) three days after initiation of therapy. The adverse event was reported to the hospital's pharmacovigilance department. The patient recovered after discontinuation of Atorvastatin and supportive care.",
    "authors":"Williams M; Rodriguez M; Rodriguez L",
    "first_author":"Williams M",
    "journal":"Drug Safety",
    "publication_year":2025,
    "create_date":"2025-12-24",
    "pmcid":"PMC5091360",
    "doi":"10.1171\/sc8qmeouzv",
    "citation":"Williams M et al. Drug Safety. 2025;51(10):353-422.",
    "product_inn":"Atorvastatin",
    "product_id":14,
    "category":"icsr_cannot_exclude",
    "adverse_events":[
      "Hepatotoxicity",
      "Elevated liver enzymes"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":false,
    "exclusion_reason":null,
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":20,
    "pmid":40683831,
    "title":"Acute Kidney Injury Associated with Cisatracurium in Elderly Patient: A Case Report",
    "abstract":"A 72-year-old female patient (ID: 2024-PV-1234) presented with acute kidney injury following treatment with Cisatracurium 1g intravenous. The case was documented by Dr. Michael Chen, nephrologist at City General Hospital. Serum creatinine increased from 1.2 mg\/dL to 3.8 mg\/dL within 48 hours of drug administration. The patient required temporary dialysis. This adverse drug reaction was classified as serious and reported to regulatory authorities.",
    "authors":"Johnson R; Davis E; Brown E; Davis J; Garcia W; Garcia D",
    "first_author":"Johnson R",
    "journal":"American Journal of Medicine",
    "publication_year":2024,
    "create_date":"2024-12-10",
    "pmcid":"",
    "doi":"10.5664\/87v0sgmaco",
    "citation":"Johnson R et al. American Journal of Medicine. 2024;125(3):735-389.",
    "product_inn":"Cisatracurium",
    "product_id":6,
    "category":"icsr_cannot_exclude",
    "adverse_events":[
      "Acute kidney injury",
      "Elevated serum creatinine"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":false,
    "exclusion_reason":null,
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":21,
    "pmid":40302891,
    "title":"Acute Kidney Injury Associated with Cisplatin in Elderly Patient: A Case Report",
    "abstract":"A 72-year-old female patient (ID: 2024-PV-1234) presented with acute kidney injury following treatment with Cisplatin 100mg intravenous. The case was documented by Dr. Michael Chen, nephrologist at City General Hospital. Serum creatinine increased from 1.2 mg\/dL to 3.8 mg\/dL within 48 hours of drug administration. The patient required temporary dialysis. This adverse drug reaction was classified as serious and reported to regulatory authorities.",
    "authors":"Brown E; Brown J; Rodriguez M; Martinez J; Johnson L",
    "first_author":"Brown E",
    "journal":"Internal Medicine",
    "publication_year":2025,
    "create_date":"2025-02-26",
    "pmcid":"",
    "doi":"10.9229\/uj1f1v7iuf",
    "citation":"Brown E et al. Internal Medicine. 2025;14(3):986-708.",
    "product_inn":"Cisplatin",
    "product_id":8,
    "category":"icsr_cannot_exclude",
    "adverse_events":[
      "Acute kidney injury",
      "Elevated serum creatinine"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":false,
    "exclusion_reason":null,
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":22,
    "pmid":40665109,
    "title":"Severe Hepatotoxicity Following Lisinopril Administration in a 45-Year-Old Male Patient",
    "abstract":"We report a case of a 45-year-old male patient (initials J.M.) who developed severe hepatotoxicity after receiving Lisinopril 80mg oral. The patient was treated by Dr. Sarah Johnson at Memorial Hospital. Laboratory findings showed elevated liver enzymes (ALT 450 U\/L, AST 380 U\/L) three days after initiation of therapy. The adverse event was reported to the hospital's pharmacovigilance department. The patient recovered after discontinuation of Lisinopril and supportive care.",
    "authors":"Smith M; Garcia S",
    "first_author":"Smith M",
    "journal":"Clinical Pharmacology & Therapeutics",
    "publication_year":2024,
    "create_date":"2024-02-08",
    "pmcid":"PMC5141702",
    "doi":"10.6235\/6jm59xe3zu",
    "citation":"Smith M et al. Clinical Pharmacology & Therapeutics. 2024;141(4):941-994.",
    "product_inn":"Lisinopril",
    "product_id":3,
    "category":"icsr_cannot_exclude",
    "adverse_events":[
      "Hepatotoxicity",
      "Elevated liver enzymes"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":false,
    "exclusion_reason":null,
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":23,
    "pmid":40146100,
    "title":"Severe Hepatotoxicity Following Metformin Administration in a 45-Year-Old Male Patient",
    "abstract":"We report a case of a 45-year-old male patient (initials J.M.) who developed severe hepatotoxicity after receiving Metformin 40mg oral. The patient was treated by Dr. Sarah Johnson at Memorial Hospital. Laboratory findings showed elevated liver enzymes (ALT 450 U\/L, AST 380 U\/L) three days after initiation of therapy. The adverse event was reported to the hospital's pharmacovigilance department. The patient recovered after discontinuation of Metformin and supportive care.",
    "authors":"Brown S; Brown D",
    "first_author":"Brown S",
    "journal":"Drug Safety",
    "publication_year":2025,
    "create_date":"2025-11-12",
    "pmcid":"",
    "doi":"10.5133\/axmrkx08rv",
    "citation":"Brown S et al. Drug Safety. 2025;61(11):932-431.",
    "product_inn":"Metformin",
    "product_id":2,
    "category":"icsr_cannot_exclude",
    "adverse_events":[
      "Hepatotoxicity",
      "Elevated liver enzymes"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":false,
    "exclusion_reason":null,
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":24,
    "pmid":40537919,
    "title":"Severe Hepatotoxicity Following Omeprazole Administration in a 45-Year-Old Male Patient",
    "abstract":"We report a case of a 45-year-old male patient (initials J.M.) who developed severe hepatotoxicity after receiving Omeprazole 40mg oral. The patient was treated by Dr. Sarah Johnson at Memorial Hospital. Laboratory findings showed elevated liver enzymes (ALT 450 U\/L, AST 380 U\/L) three days after initiation of therapy. The adverse event was reported to the hospital's pharmacovigilance department. The patient recovered after discontinuation of Omeprazole and supportive care.",
    "authors":"Davis W; Johnson J; Johnson M; Brown M; Miller W",
    "first_author":"Davis W",
    "journal":"European Journal of Clinical Pharmacology",
    "publication_year":2024,
    "create_date":"2024-05-15",
    "pmcid":"PMC6165767",
    "doi":"10.5492\/8capbwa72u",
    "citation":"Davis W et al. European Journal of Clinical Pharmacology. 2024;75(12):983-894.",
    "product_inn":"Omeprazole",
    "product_id":4,
    "category":"icsr_cannot_exclude",
    "adverse_events":[
      "Hepatotoxicity",
      "Elevated liver enzymes"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":false,
    "exclusion_reason":null,
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":25,
    "pmid":40078660,
    "title":"Anaphylactic Reaction to Omeprazole: Case Report and Literature Review",
    "abstract":"We describe a case of anaphylactic reaction in a 38-year-old male (patient code: ANP-2025-087) following intravenous administration of Omeprazole 50mg. The reaction occurred within 15 minutes of drug administration and was managed by Dr. Emily Rodriguez in the emergency department. The patient developed urticaria, bronchospasm, and hypotension (BP 80\/50 mmHg). Treatment with epinephrine, corticosteroids, and antihistamines resulted in complete recovery. This case highlights the importance of monitoring for hypersensitivity reactions.",
    "authors":"Garcia M; Johnson R; Martinez M",
    "first_author":"Garcia M",
    "journal":"Drug Safety",
    "publication_year":2024,
    "create_date":"2024-06-21",
    "pmcid":"PMC1472670",
    "doi":"10.4220\/ps1irgobh3",
    "citation":"Garcia M et al. Drug Safety. 2024;113(1):262-538.",
    "product_inn":"Omeprazole",
    "product_id":4,
    "category":"icsr_cannot_exclude",
    "adverse_events":[
      "Anaphylaxis",
      "Urticaria",
      "Bronchospasm",
      "Hypotension"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":false,
    "exclusion_reason":null,
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":26,
    "pmid":40679863,
    "title":"Anaphylactic Reaction to Methylprednisolone: Case Report and Literature Review",
    "abstract":"We describe a case of anaphylactic reaction in a 38-year-old male (patient code: ANP-2025-087) following intravenous administration of Methylprednisolone 50mg. The reaction occurred within 15 minutes of drug administration and was managed by Dr. Emily Rodriguez in the emergency department. The patient developed urticaria, bronchospasm, and hypotension (BP 80\/50 mmHg). Treatment with epinephrine, corticosteroids, and antihistamines resulted in complete recovery. This case highlights the importance of monitoring for hypersensitivity reactions.",
    "authors":"Johnson M; Jones M; Williams M",
    "first_author":"Johnson M",
    "journal":"Pharmacotherapy",
    "publication_year":2024,
    "create_date":"2024-07-25",
    "pmcid":"PMC7960686",
    "doi":"10.9228\/9neya6foet",
    "citation":"Johnson M et al. Pharmacotherapy. 2024;24(9):924-673.",
    "product_inn":"Methylprednisolone",
    "product_id":7,
    "category":"icsr_cannot_exclude",
    "adverse_events":[
      "Anaphylaxis",
      "Urticaria",
      "Bronchospasm",
      "Hypotension"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":false,
    "exclusion_reason":null,
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":27,
    "pmid":40217110,
    "title":"Severe Hepatotoxicity Following Levothyroxine Administration in a 45-Year-Old Male Patient",
    "abstract":"We report a case of a 45-year-old male patient (initials J.M.) who developed severe hepatotoxicity after receiving Levothyroxine 40mg oral. The patient was treated by Dr. Sarah Johnson at Memorial Hospital. Laboratory findings showed elevated liver enzymes (ALT 450 U\/L, AST 380 U\/L) three days after initiation of therapy. The adverse event was reported to the hospital's pharmacovigilance department. The patient recovered after discontinuation of Levothyroxine and supportive care.",
    "authors":"Smith D; Rodriguez M; Davis D; Johnson J; Garcia L",
    "first_author":"Smith D",
    "journal":"British Journal of Clinical Pharmacology",
    "publication_year":2025,
    "create_date":"2025-01-14",
    "pmcid":"",
    "doi":"10.3402\/ajehwm05p2",
    "citation":"Smith D et al. British Journal of Clinical Pharmacology. 2025;109(9):887-317.",
    "product_inn":"Levothyroxine",
    "product_id":13,
    "category":"icsr_cannot_exclude",
    "adverse_events":[
      "Hepatotoxicity",
      "Elevated liver enzymes"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":false,
    "exclusion_reason":null,
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":28,
    "pmid":40492874,
    "title":"Acute Kidney Injury Associated with Metformin in Elderly Patient: A Case Report",
    "abstract":"A 72-year-old female patient (ID: 2024-PV-1234) presented with acute kidney injury following treatment with Metformin 40mg oral. The case was documented by Dr. Michael Chen, nephrologist at City General Hospital. Serum creatinine increased from 1.2 mg\/dL to 3.8 mg\/dL within 48 hours of drug administration. The patient required temporary dialysis. This adverse drug reaction was classified as serious and reported to regulatory authorities.",
    "authors":"Smith W; Jones J",
    "first_author":"Smith W",
    "journal":"American Journal of Medicine",
    "publication_year":2025,
    "create_date":"2025-09-08",
    "pmcid":"",
    "doi":"10.1166\/odcae6o2z4",
    "citation":"Smith W et al. American Journal of Medicine. 2025;142(10):322-609.",
    "product_inn":"Metformin",
    "product_id":2,
    "category":"icsr_cannot_exclude",
    "adverse_events":[
      "Acute kidney injury",
      "Elevated serum creatinine"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":false,
    "exclusion_reason":null,
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":29,
    "pmid":40773650,
    "title":"Severe Hepatotoxicity Following Atorvastatin Administration in a 45-Year-Old Male Patient",
    "abstract":"We report a case of a 45-year-old male patient (initials J.M.) who developed severe hepatotoxicity after receiving Atorvastatin 80mg oral. The patient was treated by Dr. Sarah Johnson at Memorial Hospital. Laboratory findings showed elevated liver enzymes (ALT 450 U\/L, AST 380 U\/L) three days after initiation of therapy. The adverse event was reported to the hospital's pharmacovigilance department. The patient recovered after discontinuation of Atorvastatin and supportive care.",
    "authors":"Jones M; Martinez R",
    "first_author":"Jones M",
    "journal":"Internal Medicine",
    "publication_year":2024,
    "create_date":"2024-11-05",
    "pmcid":"PMC7801410",
    "doi":"10.1255\/45rrzyb914",
    "citation":"Jones M et al. Internal Medicine. 2024;147(8):198-937.",
    "product_inn":"Atorvastatin",
    "product_id":14,
    "category":"icsr_cannot_exclude",
    "adverse_events":[
      "Hepatotoxicity",
      "Elevated liver enzymes"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":false,
    "exclusion_reason":null,
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":30,
    "pmid":40689118,
    "title":"Acute Kidney Injury Associated with Atorvastatin in Elderly Patient: A Case Report",
    "abstract":"A 72-year-old female patient (ID: 2024-PV-1234) presented with acute kidney injury following treatment with Atorvastatin 20mg oral. The case was documented by Dr. Michael Chen, nephrologist at City General Hospital. Serum creatinine increased from 1.2 mg\/dL to 3.8 mg\/dL within 48 hours of drug administration. The patient required temporary dialysis. This adverse drug reaction was classified as serious and reported to regulatory authorities.",
    "authors":"Johnson S; Rodriguez R; Garcia W; Rodriguez D",
    "first_author":"Johnson S",
    "journal":"Drug Safety",
    "publication_year":2024,
    "create_date":"2024-02-26",
    "pmcid":"",
    "doi":"10.5999\/8basbxbdng",
    "citation":"Johnson S et al. Drug Safety. 2024;26(11):370-543.",
    "product_inn":"Atorvastatin",
    "product_id":14,
    "category":"icsr_cannot_exclude",
    "adverse_events":[
      "Acute kidney injury",
      "Elevated serum creatinine"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":false,
    "exclusion_reason":null,
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":31,
    "pmid":40109731,
    "title":"Neurological Complications with Intrathecal Doxorubicin Administration",
    "abstract":"We report a case of a 42-year-old female (patient ID: NT-2025-456) who experienced neurological complications following intrathecal administration of Doxorubicin 10mg. The case was managed by Dr. Robert Williams, neurosurgeon at Regional Medical Center. The patient developed severe headache, confusion, and seizures 24 hours post-administration. The intrathecal route of administration is not approved for this medication.",
    "authors":"Martinez M; Martinez S; Smith L; Garcia S",
    "first_author":"Martinez M",
    "journal":"Journal of Clinical Pharmacology",
    "publication_year":2025,
    "create_date":"2025-04-09",
    "pmcid":"PMC2188315",
    "doi":"10.5174\/g5tnlujyvn",
    "citation":"Martinez M et al. Journal of Clinical Pharmacology. 2025;48(6):421-480.",
    "product_inn":"Doxorubicin",
    "product_id":10,
    "category":"icsr_can_exclude",
    "adverse_events":[
      "Neurological complications",
      "Headache",
      "Confusion",
      "Seizures"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":true,
    "exclusion_reason":"Different route of administration (intrathecal) not in Hikma's approved formulations",
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":32,
    "pmid":40536397,
    "title":"Neurological Complications with Intrathecal Metronidazole Administration",
    "abstract":"We report a case of a 42-year-old female (patient ID: NT-2025-456) who experienced neurological complications following intrathecal administration of Metronidazole 10mg. The case was managed by Dr. Robert Williams, neurosurgeon at Regional Medical Center. The patient developed severe headache, confusion, and seizures 24 hours post-administration. The intrathecal route of administration is not approved for this medication.",
    "authors":"Williams J; Smith D; Rodriguez J; Rodriguez S",
    "first_author":"Williams J",
    "journal":"Drug Safety",
    "publication_year":2025,
    "create_date":"2025-08-14",
    "pmcid":"PMC5916998",
    "doi":"10.4894\/c3t4vqhu47",
    "citation":"Williams J et al. Drug Safety. 2025;87(1):337-107.",
    "product_inn":"Metronidazole",
    "product_id":9,
    "category":"icsr_can_exclude",
    "adverse_events":[
      "Neurological complications",
      "Headache",
      "Confusion",
      "Seizures"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":true,
    "exclusion_reason":"Different route of administration (intrathecal) not in Hikma's approved formulations",
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":33,
    "pmid":40680968,
    "title":"Neurological Complications with Intrathecal Omeprazole Administration",
    "abstract":"We report a case of a 42-year-old female (patient ID: NT-2025-456) who experienced neurological complications following intrathecal administration of Omeprazole 10mg. The case was managed by Dr. Robert Williams, neurosurgeon at Regional Medical Center. The patient developed severe headache, confusion, and seizures 24 hours post-administration. The intrathecal route of administration is not approved for this medication.",
    "authors":"Rodriguez R; Smith L; Rodriguez J; Johnson M; Brown W; Brown S",
    "first_author":"Rodriguez R",
    "journal":"Clinical Pharmacology & Therapeutics",
    "publication_year":2024,
    "create_date":"2024-09-06",
    "pmcid":"",
    "doi":"10.4476\/4doci1c347",
    "citation":"Rodriguez R et al. Clinical Pharmacology & Therapeutics. 2024;145(7):211-861.",
    "product_inn":"Omeprazole",
    "product_id":4,
    "category":"icsr_can_exclude",
    "adverse_events":[
      "Neurological complications",
      "Headache",
      "Confusion",
      "Seizures"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":true,
    "exclusion_reason":"Different route of administration (intrathecal) not in Hikma's approved formulations",
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":34,
    "pmid":40884323,
    "title":"Neurological Complications with Intrathecal Atorvastatin Administration",
    "abstract":"We report a case of a 42-year-old female (patient ID: NT-2025-456) who experienced neurological complications following intrathecal administration of Atorvastatin 10mg. The case was managed by Dr. Robert Williams, neurosurgeon at Regional Medical Center. The patient developed severe headache, confusion, and seizures 24 hours post-administration. The intrathecal route of administration is not approved for this medication.",
    "authors":"Rodriguez M; Martinez D; Brown D; Brown E",
    "first_author":"Rodriguez M",
    "journal":"Clinical Pharmacology & Therapeutics",
    "publication_year":2025,
    "create_date":"2025-01-12",
    "pmcid":"",
    "doi":"10.3224\/t3625txu5s",
    "citation":"Rodriguez M et al. Clinical Pharmacology & Therapeutics. 2025;99(6):487-858.",
    "product_inn":"Atorvastatin",
    "product_id":14,
    "category":"icsr_can_exclude",
    "adverse_events":[
      "Neurological complications",
      "Headache",
      "Confusion",
      "Seizures"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":true,
    "exclusion_reason":"Different route of administration (intrathecal) not in Hikma's approved formulations",
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":35,
    "pmid":40617770,
    "title":"Cardiotoxicity Following Losartan Treatment in Japanese Population",
    "abstract":"A 55-year-old male patient (initials T.K.) from Tokyo, Japan, developed cardiotoxicity after receiving Losartan manufactured by Takeda Pharmaceuticals. The patient was under the care of Dr. Hiroshi Yamamoto at Tokyo Medical Center. Echocardiography revealed reduced ejection fraction (35%) after three cycles of chemotherapy. The brand name Takeda-Losartan was confirmed from the medication records. The patient's condition improved with dose reduction and cardiac supportive therapy.",
    "authors":"Garcia E; Brown W; Davis M; Smith M; Martinez L",
    "first_author":"Garcia E",
    "journal":"Journal of Medical Case Reports",
    "publication_year":2024,
    "create_date":"2024-06-26",
    "pmcid":"",
    "doi":"10.7587\/gcnjsigyyd",
    "citation":"Garcia E et al. Journal of Medical Case Reports. 2024;11(7):563-259.",
    "product_inn":"Losartan",
    "product_id":15,
    "category":"icsr_can_exclude",
    "adverse_events":[
      "Cardiotoxicity",
      "Reduced ejection fraction"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":true,
    "exclusion_reason":"Different manufacturer (Takeda Pharmaceuticals) and territory (Japan) not covered by Hikma",
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":36,
    "pmid":40232433,
    "title":"Cardiotoxicity Following Methylprednisolone Treatment in Japanese Population",
    "abstract":"A 55-year-old male patient (initials T.K.) from Tokyo, Japan, developed cardiotoxicity after receiving Methylprednisolone manufactured by Takeda Pharmaceuticals. The patient was under the care of Dr. Hiroshi Yamamoto at Tokyo Medical Center. Echocardiography revealed reduced ejection fraction (35%) after three cycles of chemotherapy. The brand name Takeda-Methylprednisolone was confirmed from the medication records. The patient's condition improved with dose reduction and cardiac supportive therapy.",
    "authors":"Davis W; Rodriguez J; Garcia E; Garcia L",
    "first_author":"Davis W",
    "journal":"British Journal of Clinical Pharmacology",
    "publication_year":2024,
    "create_date":"2024-06-28",
    "pmcid":"",
    "doi":"10.8552\/srecpyd12t",
    "citation":"Davis W et al. British Journal of Clinical Pharmacology. 2024;15(9):203-767.",
    "product_inn":"Methylprednisolone",
    "product_id":7,
    "category":"icsr_can_exclude",
    "adverse_events":[
      "Cardiotoxicity",
      "Reduced ejection fraction"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":true,
    "exclusion_reason":"Different manufacturer (Takeda Pharmaceuticals) and territory (Japan) not covered by Hikma",
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":37,
    "pmid":40437109,
    "title":"Severe Skin Reaction to Doxorubicin Transdermal Patch",
    "abstract":"A 60-year-old male patient (initials R.P.) developed severe contact dermatitis after application of Doxorubicin transdermal patch. Dr. Lisa Anderson, dermatologist at Skin Care Clinic, documented the case. The patient presented with erythema, vesicles, and intense pruritus at the application site. Patch testing confirmed hypersensitivity to the adhesive component. The transdermal formulation was discontinued.",
    "authors":"Davis S; Jones S; Garcia M",
    "first_author":"Davis S",
    "journal":"Internal Medicine",
    "publication_year":2024,
    "create_date":"2024-12-06",
    "pmcid":"",
    "doi":"10.4349\/8yznps56yr",
    "citation":"Davis S et al. Internal Medicine. 2024;44(4):285-371.",
    "product_inn":"Doxorubicin",
    "product_id":10,
    "category":"icsr_can_exclude",
    "adverse_events":[
      "Contact dermatitis",
      "Erythema",
      "Vesicles",
      "Pruritus"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":true,
    "exclusion_reason":"Different dosage form (transdermal patch) not manufactured by Hikma",
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":38,
    "pmid":40610563,
    "title":"Cardiotoxicity Following Insulin Glargine Treatment in Japanese Population",
    "abstract":"A 55-year-old male patient (initials T.K.) from Tokyo, Japan, developed cardiotoxicity after receiving Insulin Glargine manufactured by Takeda Pharmaceuticals. The patient was under the care of Dr. Hiroshi Yamamoto at Tokyo Medical Center. Echocardiography revealed reduced ejection fraction (35%) after three cycles of chemotherapy. The brand name Takeda-Insulin Glargine was confirmed from the medication records. The patient's condition improved with dose reduction and cardiac supportive therapy.",
    "authors":"Garcia M; Rodriguez E; Smith M",
    "first_author":"Garcia M",
    "journal":"American Journal of Medicine",
    "publication_year":2024,
    "create_date":"2024-04-23",
    "pmcid":"PMC5362309",
    "doi":"10.5577\/goaetmwm21",
    "citation":"Garcia M et al. American Journal of Medicine. 2024;61(10):247-674.",
    "product_inn":"Insulin Glargine",
    "product_id":12,
    "category":"icsr_can_exclude",
    "adverse_events":[
      "Cardiotoxicity",
      "Reduced ejection fraction"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":true,
    "exclusion_reason":"Different manufacturer (Takeda Pharmaceuticals) and territory (Japan) not covered by Hikma",
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":39,
    "pmid":40785260,
    "title":"Neurological Complications with Intrathecal Omeprazole Administration",
    "abstract":"We report a case of a 42-year-old female (patient ID: NT-2025-456) who experienced neurological complications following intrathecal administration of Omeprazole 10mg. The case was managed by Dr. Robert Williams, neurosurgeon at Regional Medical Center. The patient developed severe headache, confusion, and seizures 24 hours post-administration. The intrathecal route of administration is not approved for this medication.",
    "authors":"Johnson M; Miller D; Rodriguez J; Smith R",
    "first_author":"Johnson M",
    "journal":"Drug Safety",
    "publication_year":2024,
    "create_date":"2024-07-22",
    "pmcid":"",
    "doi":"10.6410\/garppthk9f",
    "citation":"Johnson M et al. Drug Safety. 2024;107(9):349-167.",
    "product_inn":"Omeprazole",
    "product_id":4,
    "category":"icsr_can_exclude",
    "adverse_events":[
      "Neurological complications",
      "Headache",
      "Confusion",
      "Seizures"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":true,
    "exclusion_reason":"Different route of administration (intrathecal) not in Hikma's approved formulations",
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":40,
    "pmid":40476970,
    "title":"Neurological Complications with Intrathecal Amlodipine Administration",
    "abstract":"We report a case of a 42-year-old female (patient ID: NT-2025-456) who experienced neurological complications following intrathecal administration of Amlodipine 10mg. The case was managed by Dr. Robert Williams, neurosurgeon at Regional Medical Center. The patient developed severe headache, confusion, and seizures 24 hours post-administration. The intrathecal route of administration is not approved for this medication.",
    "authors":"Johnson D; Miller J; Brown R",
    "first_author":"Johnson D",
    "journal":"European Journal of Clinical Pharmacology",
    "publication_year":2024,
    "create_date":"2024-05-06",
    "pmcid":"PMC5961680",
    "doi":"10.5839\/5tkrqaody4",
    "citation":"Johnson D et al. European Journal of Clinical Pharmacology. 2024;39(1):797-361.",
    "product_inn":"Amlodipine",
    "product_id":1,
    "category":"icsr_can_exclude",
    "adverse_events":[
      "Neurological complications",
      "Headache",
      "Confusion",
      "Seizures"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":true,
    "exclusion_reason":"Different route of administration (intrathecal) not in Hikma's approved formulations",
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":41,
    "pmid":40336899,
    "title":"Severe Skin Reaction to Methylprednisolone Transdermal Patch",
    "abstract":"A 60-year-old male patient (initials R.P.) developed severe contact dermatitis after application of Methylprednisolone transdermal patch. Dr. Lisa Anderson, dermatologist at Skin Care Clinic, documented the case. The patient presented with erythema, vesicles, and intense pruritus at the application site. Patch testing confirmed hypersensitivity to the adhesive component. The transdermal formulation was discontinued.",
    "authors":"Rodriguez D; Davis J",
    "first_author":"Rodriguez D",
    "journal":"Drug Safety",
    "publication_year":2025,
    "create_date":"2025-09-23",
    "pmcid":"PMC8684914",
    "doi":"10.6368\/inluajfpda",
    "citation":"Rodriguez D et al. Drug Safety. 2025;11(12):243-103.",
    "product_inn":"Methylprednisolone",
    "product_id":7,
    "category":"icsr_can_exclude",
    "adverse_events":[
      "Contact dermatitis",
      "Erythema",
      "Vesicles",
      "Pruritus"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":true,
    "exclusion_reason":"Different dosage form (transdermal patch) not manufactured by Hikma",
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":42,
    "pmid":40782849,
    "title":"Neurological Complications with Intrathecal Metformin Administration",
    "abstract":"We report a case of a 42-year-old female (patient ID: NT-2025-456) who experienced neurological complications following intrathecal administration of Metformin 10mg. The case was managed by Dr. Robert Williams, neurosurgeon at Regional Medical Center. The patient developed severe headache, confusion, and seizures 24 hours post-administration. The intrathecal route of administration is not approved for this medication.",
    "authors":"Rodriguez R; Smith E; Williams J; Garcia M; Jones M",
    "first_author":"Rodriguez R",
    "journal":"British Journal of Clinical Pharmacology",
    "publication_year":2024,
    "create_date":"2024-08-22",
    "pmcid":"",
    "doi":"10.6357\/zxzkjupiet",
    "citation":"Rodriguez R et al. British Journal of Clinical Pharmacology. 2024;144(1):228-904.",
    "product_inn":"Metformin",
    "product_id":2,
    "category":"icsr_can_exclude",
    "adverse_events":[
      "Neurological complications",
      "Headache",
      "Confusion",
      "Seizures"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":true,
    "exclusion_reason":"Different route of administration (intrathecal) not in Hikma's approved formulations",
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":43,
    "pmid":40978835,
    "title":"Neurological Complications with Intrathecal Atorvastatin Administration",
    "abstract":"We report a case of a 42-year-old female (patient ID: NT-2025-456) who experienced neurological complications following intrathecal administration of Atorvastatin 10mg. The case was managed by Dr. Robert Williams, neurosurgeon at Regional Medical Center. The patient developed severe headache, confusion, and seizures 24 hours post-administration. The intrathecal route of administration is not approved for this medication.",
    "authors":"Garcia E; Johnson R; Smith R",
    "first_author":"Garcia E",
    "journal":"Drug Safety",
    "publication_year":2025,
    "create_date":"2025-10-28",
    "pmcid":"PMC7267051",
    "doi":"10.3944\/bpe4bbk9b9",
    "citation":"Garcia E et al. Drug Safety. 2025;48(7):374-611.",
    "product_inn":"Atorvastatin",
    "product_id":14,
    "category":"icsr_can_exclude",
    "adverse_events":[
      "Neurological complications",
      "Headache",
      "Confusion",
      "Seizures"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":true,
    "exclusion_reason":"Different route of administration (intrathecal) not in Hikma's approved formulations",
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":44,
    "pmid":40678667,
    "title":"Neurological Complications with Intrathecal Cisplatin Administration",
    "abstract":"We report a case of a 42-year-old female (patient ID: NT-2025-456) who experienced neurological complications following intrathecal administration of Cisplatin 10mg. The case was managed by Dr. Robert Williams, neurosurgeon at Regional Medical Center. The patient developed severe headache, confusion, and seizures 24 hours post-administration. The intrathecal route of administration is not approved for this medication.",
    "authors":"Rodriguez L; Smith S; Johnson E",
    "first_author":"Rodriguez L",
    "journal":"Journal of Clinical Pharmacology",
    "publication_year":2025,
    "create_date":"2025-01-20",
    "pmcid":"",
    "doi":"10.5601\/le9doynbed",
    "citation":"Rodriguez L et al. Journal of Clinical Pharmacology. 2025;24(10):897-219.",
    "product_inn":"Cisplatin",
    "product_id":8,
    "category":"icsr_can_exclude",
    "adverse_events":[
      "Neurological complications",
      "Headache",
      "Confusion",
      "Seizures"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":true,
    "exclusion_reason":"Different route of administration (intrathecal) not in Hikma's approved formulations",
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":45,
    "pmid":40666706,
    "title":"Neurological Complications with Intrathecal Atorvastatin Administration",
    "abstract":"We report a case of a 42-year-old female (patient ID: NT-2025-456) who experienced neurological complications following intrathecal administration of Atorvastatin 10mg. The case was managed by Dr. Robert Williams, neurosurgeon at Regional Medical Center. The patient developed severe headache, confusion, and seizures 24 hours post-administration. The intrathecal route of administration is not approved for this medication.",
    "authors":"Smith S; Johnson W; Johnson M; Jones W",
    "first_author":"Smith S",
    "journal":"British Journal of Clinical Pharmacology",
    "publication_year":2024,
    "create_date":"2024-08-13",
    "pmcid":"",
    "doi":"10.4833\/2jz9qqzz6n",
    "citation":"Smith S et al. British Journal of Clinical Pharmacology. 2024;140(1):113-706.",
    "product_inn":"Atorvastatin",
    "product_id":14,
    "category":"icsr_can_exclude",
    "adverse_events":[
      "Neurological complications",
      "Headache",
      "Confusion",
      "Seizures"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":true,
    "exclusion_reason":"Different route of administration (intrathecal) not in Hikma's approved formulations",
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":46,
    "pmid":40750122,
    "title":"Cardiotoxicity Following Lisinopril Treatment in Japanese Population",
    "abstract":"A 55-year-old male patient (initials T.K.) from Tokyo, Japan, developed cardiotoxicity after receiving Lisinopril manufactured by Takeda Pharmaceuticals. The patient was under the care of Dr. Hiroshi Yamamoto at Tokyo Medical Center. Echocardiography revealed reduced ejection fraction (35%) after three cycles of chemotherapy. The brand name Takeda-Lisinopril was confirmed from the medication records. The patient's condition improved with dose reduction and cardiac supportive therapy.",
    "authors":"Rodriguez D; Jones M; Davis M; Martinez W; Brown E; Garcia M",
    "first_author":"Rodriguez D",
    "journal":"European Journal of Clinical Pharmacology",
    "publication_year":2024,
    "create_date":"2024-06-02",
    "pmcid":"",
    "doi":"10.1916\/e99dmo5gfv",
    "citation":"Rodriguez D et al. European Journal of Clinical Pharmacology. 2024;50(3):187-569.",
    "product_inn":"Lisinopril",
    "product_id":3,
    "category":"icsr_can_exclude",
    "adverse_events":[
      "Cardiotoxicity",
      "Reduced ejection fraction"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":true,
    "exclusion_reason":"Different manufacturer (Takeda Pharmaceuticals) and territory (Japan) not covered by Hikma",
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":47,
    "pmid":40366845,
    "title":"Cardiotoxicity Following Insulin Glargine Treatment in Japanese Population",
    "abstract":"A 55-year-old male patient (initials T.K.) from Tokyo, Japan, developed cardiotoxicity after receiving Insulin Glargine manufactured by Takeda Pharmaceuticals. The patient was under the care of Dr. Hiroshi Yamamoto at Tokyo Medical Center. Echocardiography revealed reduced ejection fraction (35%) after three cycles of chemotherapy. The brand name Takeda-Insulin Glargine was confirmed from the medication records. The patient's condition improved with dose reduction and cardiac supportive therapy.",
    "authors":"Davis E; Martinez J; Smith W; Rodriguez J",
    "first_author":"Davis E",
    "journal":"BMC Pharmacology and Toxicology",
    "publication_year":2025,
    "create_date":"2025-06-15",
    "pmcid":"",
    "doi":"10.5978\/u4iftsstwv",
    "citation":"Davis E et al. BMC Pharmacology and Toxicology. 2025;100(1):380-976.",
    "product_inn":"Insulin Glargine",
    "product_id":12,
    "category":"icsr_can_exclude",
    "adverse_events":[
      "Cardiotoxicity",
      "Reduced ejection fraction"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":true,
    "exclusion_reason":"Different manufacturer (Takeda Pharmaceuticals) and territory (Japan) not covered by Hikma",
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":48,
    "pmid":40145703,
    "title":"Neurological Complications with Intrathecal Cisatracurium Administration",
    "abstract":"We report a case of a 42-year-old female (patient ID: NT-2025-456) who experienced neurological complications following intrathecal administration of Cisatracurium 10mg. The case was managed by Dr. Robert Williams, neurosurgeon at Regional Medical Center. The patient developed severe headache, confusion, and seizures 24 hours post-administration. The intrathecal route of administration is not approved for this medication.",
    "authors":"Rodriguez J; Johnson S; Davis M",
    "first_author":"Rodriguez J",
    "journal":"Internal Medicine",
    "publication_year":2025,
    "create_date":"2025-07-24",
    "pmcid":"",
    "doi":"10.4609\/hh2nbspgoe",
    "citation":"Rodriguez J et al. Internal Medicine. 2025;80(1):759-616.",
    "product_inn":"Cisatracurium",
    "product_id":6,
    "category":"icsr_can_exclude",
    "adverse_events":[
      "Neurological complications",
      "Headache",
      "Confusion",
      "Seizures"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":true,
    "exclusion_reason":"Different route of administration (intrathecal) not in Hikma's approved formulations",
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":49,
    "pmid":40524358,
    "title":"Neurological Complications with Intrathecal Warfarin Administration",
    "abstract":"We report a case of a 42-year-old female (patient ID: NT-2025-456) who experienced neurological complications following intrathecal administration of Warfarin 10mg. The case was managed by Dr. Robert Williams, neurosurgeon at Regional Medical Center. The patient developed severe headache, confusion, and seizures 24 hours post-administration. The intrathecal route of administration is not approved for this medication.",
    "authors":"Williams E; Brown S; Smith E; Rodriguez D; Davis S; Martinez J",
    "first_author":"Williams E",
    "journal":"British Journal of Clinical Pharmacology",
    "publication_year":2025,
    "create_date":"2025-11-23",
    "pmcid":"",
    "doi":"10.6396\/sc9vtaeqoc",
    "citation":"Williams E et al. British Journal of Clinical Pharmacology. 2025;60(7):556-334.",
    "product_inn":"Warfarin",
    "product_id":11,
    "category":"icsr_can_exclude",
    "adverse_events":[
      "Neurological complications",
      "Headache",
      "Confusion",
      "Seizures"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":true,
    "exclusion_reason":"Different route of administration (intrathecal) not in Hikma's approved formulations",
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":50,
    "pmid":40298796,
    "title":"Neurological Complications with Intrathecal Lisinopril Administration",
    "abstract":"We report a case of a 42-year-old female (patient ID: NT-2025-456) who experienced neurological complications following intrathecal administration of Lisinopril 10mg. The case was managed by Dr. Robert Williams, neurosurgeon at Regional Medical Center. The patient developed severe headache, confusion, and seizures 24 hours post-administration. The intrathecal route of administration is not approved for this medication.",
    "authors":"Brown S; Rodriguez J",
    "first_author":"Brown S",
    "journal":"Internal Medicine",
    "publication_year":2024,
    "create_date":"2024-12-23",
    "pmcid":"PMC5171677",
    "doi":"10.4690\/2820cni8a4",
    "citation":"Brown S et al. Internal Medicine. 2024;34(12):712-827.",
    "product_inn":"Lisinopril",
    "product_id":3,
    "category":"icsr_can_exclude",
    "adverse_events":[
      "Neurological complications",
      "Headache",
      "Confusion",
      "Seizures"
    ],
    "has_all_icsr_criteria":true,
    "ownership_excluded":true,
    "exclusion_reason":"Different route of administration (intrathecal) not in Hikma's approved formulations",
    "is_relevant_safety_info":null,
    "justification":""
  },
  {
    "id":51,
    "pmid":40632201,
    "title":"Comparative Safety Analysis of Losartan vs Alternative Therapies in Elderly Patients",
    "abstract":"This comparative study analyzed safety outcomes of Losartan versus alternative therapies in 300 elderly patients (age >65 years). The primary endpoint was incidence of adverse drug reactions. Losartan showed a favorable safety profile with lower rates of serious adverse events (4.2% vs 7.8%, p=0.03). Common adverse reactions included mild gastrointestinal symptoms and dizziness. The study supports the use of Losartan in elderly populations with appropriate monitoring.",
    "authors":"Martinez J; Johnson W; Martinez L; Williams M",
    "first_author":"Martinez J",
    "journal":"British Journal of Clinical Pharmacology",
    "publication_year":2024,
    "create_date":"2024-03-07",
    "pmcid":"",
    "doi":"10.8807\/ym2d1ga54n",
    "citation":"Martinez J et al. British Journal of Clinical Pharmacology. 2024;81(3):614-490.",
    "product_inn":"Losartan",
    "product_id":15,
    "category":"relevant_safety_info",
    "adverse_events":[
      "Gastrointestinal symptoms",
      "Dizziness"
    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":true,
    "justification":"Comparative safety data in special population (elderly) relevant for risk management activities"
  },
  {
    "id":52,
    "pmid":40641202,
    "title":"Comparative Safety Analysis of Amlodipine vs Alternative Therapies in Elderly Patients",
    "abstract":"This comparative study analyzed safety outcomes of Amlodipine versus alternative therapies in 300 elderly patients (age >65 years). The primary endpoint was incidence of adverse drug reactions. Amlodipine showed a favorable safety profile with lower rates of serious adverse events (4.2% vs 7.8%, p=0.03). Common adverse reactions included mild gastrointestinal symptoms and dizziness. The study supports the use of Amlodipine in elderly populations with appropriate monitoring.",
    "authors":"Davis W; Davis J; Garcia M; Jones M; Garcia R",
    "first_author":"Davis W",
    "journal":"British Journal of Clinical Pharmacology",
    "publication_year":2025,
    "create_date":"2025-12-05",
    "pmcid":"",
    "doi":"10.3840\/tei1iwmyv8",
    "citation":"Davis W et al. British Journal of Clinical Pharmacology. 2025;11(1):576-681.",
    "product_inn":"Amlodipine",
    "product_id":1,
    "category":"relevant_safety_info",
    "adverse_events":[
      "Gastrointestinal symptoms",
      "Dizziness"
    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":true,
    "justification":"Comparative safety data in special population (elderly) relevant for risk management activities"
  },
  {
    "id":53,
    "pmid":40043971,
    "title":"Comparative Safety Analysis of Methylprednisolone vs Alternative Therapies in Elderly Patients",
    "abstract":"This comparative study analyzed safety outcomes of Methylprednisolone versus alternative therapies in 300 elderly patients (age >65 years). The primary endpoint was incidence of adverse drug reactions. Methylprednisolone showed a favorable safety profile with lower rates of serious adverse events (4.2% vs 7.8%, p=0.03). Common adverse reactions included mild gastrointestinal symptoms and dizziness. The study supports the use of Methylprednisolone in elderly populations with appropriate monitoring.",
    "authors":"Miller R; Jones M; Davis J; Jones W; Williams S; Rodriguez M",
    "first_author":"Miller R",
    "journal":"European Journal of Clinical Pharmacology",
    "publication_year":2024,
    "create_date":"2024-08-03",
    "pmcid":"",
    "doi":"10.7316\/7u4k617qcy",
    "citation":"Miller R et al. European Journal of Clinical Pharmacology. 2024;134(4):499-863.",
    "product_inn":"Methylprednisolone",
    "product_id":7,
    "category":"relevant_safety_info",
    "adverse_events":[
      "Gastrointestinal symptoms",
      "Dizziness"
    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":true,
    "justification":"Comparative safety data in special population (elderly) relevant for risk management activities"
  },
  {
    "id":54,
    "pmid":40599090,
    "title":"Long-term Cardiovascular Outcomes with Metronidazole Therapy: 5-Year Follow-up Data",
    "abstract":"We present 5-year follow-up data from a cohort of 500 patients treated with Metronidazole for cardiovascular disease prevention. The study assessed major adverse cardiovascular events (MACE), including myocardial infarction, stroke, and cardiovascular death. MACE occurred in 8.5% of patients. Common adverse effects included myalgia (15%), gastrointestinal disturbances (10%), and elevated liver enzymes (3%). The benefit-risk profile remained favorable throughout the follow-up period.",
    "authors":"Garcia M; Miller M",
    "first_author":"Garcia M",
    "journal":"Internal Medicine",
    "publication_year":2025,
    "create_date":"2025-09-07",
    "pmcid":"",
    "doi":"10.3981\/w1dp2sg99y",
    "citation":"Garcia M et al. Internal Medicine. 2025;30(4):465-415.",
    "product_inn":"Metronidazole",
    "product_id":9,
    "category":"relevant_safety_info",
    "adverse_events":[
      "Myalgia",
      "Gastrointestinal disturbances",
      "Elevated liver enzymes"
    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":true,
    "justification":"Long-term safety data from large cohort useful for periodic safety update reports"
  },
  {
    "id":55,
    "pmid":40572907,
    "title":"Comparative Safety Analysis of Warfarin vs Alternative Therapies in Elderly Patients",
    "abstract":"This comparative study analyzed safety outcomes of Warfarin versus alternative therapies in 300 elderly patients (age >65 years). The primary endpoint was incidence of adverse drug reactions. Warfarin showed a favorable safety profile with lower rates of serious adverse events (4.2% vs 7.8%, p=0.03). Common adverse reactions included mild gastrointestinal symptoms and dizziness. The study supports the use of Warfarin in elderly populations with appropriate monitoring.",
    "authors":"Johnson J; Jones L; Brown S; Smith J",
    "first_author":"Johnson J",
    "journal":"Drug Safety",
    "publication_year":2025,
    "create_date":"2025-09-03",
    "pmcid":"",
    "doi":"10.7140\/3005z490rj",
    "citation":"Johnson J et al. Drug Safety. 2025;19(1):986-671.",
    "product_inn":"Warfarin",
    "product_id":11,
    "category":"relevant_safety_info",
    "adverse_events":[
      "Gastrointestinal symptoms",
      "Dizziness"
    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":true,
    "justification":"Comparative safety data in special population (elderly) relevant for risk management activities"
  },
  {
    "id":56,
    "pmid":40362435,
    "title":"Efficacy and Safety of Levothyroxine in Treatment of Refractory Hypertension: A Retrospective Study",
    "abstract":"This retrospective study evaluated the efficacy and safety of Levothyroxine in 150 patients with refractory hypertension over a 12-month period. The study was conducted at five medical centers. Mean blood pressure reduction was 18\/12 mmHg. Adverse events were mild and included dizziness (12%), headache (8%), and fatigue (5%). No serious adverse events were reported. Levothyroxine demonstrated good tolerability and efficacy in this patient population.",
    "authors":"Johnson L; Brown L; Brown W",
    "first_author":"Johnson L",
    "journal":"Clinical Pharmacology & Therapeutics",
    "publication_year":2025,
    "create_date":"2025-02-10",
    "pmcid":"PMC8361274",
    "doi":"10.2533\/52z3p0b39e",
    "citation":"Johnson L et al. Clinical Pharmacology & Therapeutics. 2025;73(8):438-949.",
    "product_inn":"Levothyroxine",
    "product_id":13,
    "category":"relevant_safety_info",
    "adverse_events":[
      "Dizziness",
      "Headache",
      "Fatigue"
    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":true,
    "justification":"Population study with safety and efficacy data useful for aggregate reporting and signal detection"
  },
  {
    "id":57,
    "pmid":40576195,
    "title":"Efficacy and Safety of Simvastatin in Treatment of Refractory Hypertension: A Retrospective Study",
    "abstract":"This retrospective study evaluated the efficacy and safety of Simvastatin in 150 patients with refractory hypertension over a 12-month period. The study was conducted at five medical centers. Mean blood pressure reduction was 18\/12 mmHg. Adverse events were mild and included dizziness (12%), headache (8%), and fatigue (5%). No serious adverse events were reported. Simvastatin demonstrated good tolerability and efficacy in this patient population.",
    "authors":"Johnson E; Davis M; Garcia J; Davis D",
    "first_author":"Johnson E",
    "journal":"Journal of Clinical Pharmacology",
    "publication_year":2024,
    "create_date":"2024-08-23",
    "pmcid":"PMC5324747",
    "doi":"10.3753\/ttb00hq421",
    "citation":"Johnson E et al. Journal of Clinical Pharmacology. 2024;102(1):995-947.",
    "product_inn":"Simvastatin",
    "product_id":5,
    "category":"relevant_safety_info",
    "adverse_events":[
      "Dizziness",
      "Headache",
      "Fatigue"
    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":true,
    "justification":"Population study with safety and efficacy data useful for aggregate reporting and signal detection"
  },
  {
    "id":58,
    "pmid":40569240,
    "title":"Comparative Safety Analysis of Warfarin vs Alternative Therapies in Elderly Patients",
    "abstract":"This comparative study analyzed safety outcomes of Warfarin versus alternative therapies in 300 elderly patients (age >65 years). The primary endpoint was incidence of adverse drug reactions. Warfarin showed a favorable safety profile with lower rates of serious adverse events (4.2% vs 7.8%, p=0.03). Common adverse reactions included mild gastrointestinal symptoms and dizziness. The study supports the use of Warfarin in elderly populations with appropriate monitoring.",
    "authors":"Williams E; Martinez M; Rodriguez J; Rodriguez D; Davis E; Smith M",
    "first_author":"Williams E",
    "journal":"BMC Pharmacology and Toxicology",
    "publication_year":2024,
    "create_date":"2024-05-22",
    "pmcid":"PMC5673857",
    "doi":"10.9591\/2ga82frh79",
    "citation":"Williams E et al. BMC Pharmacology and Toxicology. 2024;139(10):931-291.",
    "product_inn":"Warfarin",
    "product_id":11,
    "category":"relevant_safety_info",
    "adverse_events":[
      "Gastrointestinal symptoms",
      "Dizziness"
    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":true,
    "justification":"Comparative safety data in special population (elderly) relevant for risk management activities"
  },
  {
    "id":59,
    "pmid":40293474,
    "title":"Comparative Safety Analysis of Insulin Glargine vs Alternative Therapies in Elderly Patients",
    "abstract":"This comparative study analyzed safety outcomes of Insulin Glargine versus alternative therapies in 300 elderly patients (age >65 years). The primary endpoint was incidence of adverse drug reactions. Insulin Glargine showed a favorable safety profile with lower rates of serious adverse events (4.2% vs 7.8%, p=0.03). Common adverse reactions included mild gastrointestinal symptoms and dizziness. The study supports the use of Insulin Glargine in elderly populations with appropriate monitoring.",
    "authors":"Garcia E; Rodriguez J",
    "first_author":"Garcia E",
    "journal":"Journal of Medical Case Reports",
    "publication_year":2025,
    "create_date":"2025-09-06",
    "pmcid":"",
    "doi":"10.5798\/2uiwepwkla",
    "citation":"Garcia E et al. Journal of Medical Case Reports. 2025;44(6):584-708.",
    "product_inn":"Insulin Glargine",
    "product_id":12,
    "category":"relevant_safety_info",
    "adverse_events":[
      "Gastrointestinal symptoms",
      "Dizziness"
    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":true,
    "justification":"Comparative safety data in special population (elderly) relevant for risk management activities"
  },
  {
    "id":60,
    "pmid":40591984,
    "title":"Long-term Cardiovascular Outcomes with Metronidazole Therapy: 5-Year Follow-up Data",
    "abstract":"We present 5-year follow-up data from a cohort of 500 patients treated with Metronidazole for cardiovascular disease prevention. The study assessed major adverse cardiovascular events (MACE), including myocardial infarction, stroke, and cardiovascular death. MACE occurred in 8.5% of patients. Common adverse effects included myalgia (15%), gastrointestinal disturbances (10%), and elevated liver enzymes (3%). The benefit-risk profile remained favorable throughout the follow-up period.",
    "authors":"Jones R; Jones D; Johnson J; Rodriguez D; Rodriguez W",
    "first_author":"Jones R",
    "journal":"Drug Safety",
    "publication_year":2024,
    "create_date":"2024-04-02",
    "pmcid":"PMC6455652",
    "doi":"10.4333\/ut9h3fh8j3",
    "citation":"Jones R et al. Drug Safety. 2024;98(5):422-468.",
    "product_inn":"Metronidazole",
    "product_id":9,
    "category":"relevant_safety_info",
    "adverse_events":[
      "Myalgia",
      "Gastrointestinal disturbances",
      "Elevated liver enzymes"
    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":true,
    "justification":"Long-term safety data from large cohort useful for periodic safety update reports"
  },
  {
    "id":61,
    "pmid":40276924,
    "title":"Long-term Cardiovascular Outcomes with Cisplatin Therapy: 5-Year Follow-up Data",
    "abstract":"We present 5-year follow-up data from a cohort of 500 patients treated with Cisplatin for cardiovascular disease prevention. The study assessed major adverse cardiovascular events (MACE), including myocardial infarction, stroke, and cardiovascular death. MACE occurred in 8.5% of patients. Common adverse effects included myalgia (15%), gastrointestinal disturbances (10%), and elevated liver enzymes (3%). The benefit-risk profile remained favorable throughout the follow-up period.",
    "authors":"Johnson M; Jones J; Smith D; Miller W; Miller J; Miller M",
    "first_author":"Johnson M",
    "journal":"Journal of Clinical Pharmacology",
    "publication_year":2025,
    "create_date":"2025-11-15",
    "pmcid":"",
    "doi":"10.1659\/popmlu161i",
    "citation":"Johnson M et al. Journal of Clinical Pharmacology. 2025;143(6):809-742.",
    "product_inn":"Cisplatin",
    "product_id":8,
    "category":"relevant_safety_info",
    "adverse_events":[
      "Myalgia",
      "Gastrointestinal disturbances",
      "Elevated liver enzymes"
    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":true,
    "justification":"Long-term safety data from large cohort useful for periodic safety update reports"
  },
  {
    "id":62,
    "pmid":40011175,
    "title":"Long-term Cardiovascular Outcomes with Losartan Therapy: 5-Year Follow-up Data",
    "abstract":"We present 5-year follow-up data from a cohort of 500 patients treated with Losartan for cardiovascular disease prevention. The study assessed major adverse cardiovascular events (MACE), including myocardial infarction, stroke, and cardiovascular death. MACE occurred in 8.5% of patients. Common adverse effects included myalgia (15%), gastrointestinal disturbances (10%), and elevated liver enzymes (3%). The benefit-risk profile remained favorable throughout the follow-up period.",
    "authors":"Brown W; Garcia W",
    "first_author":"Brown W",
    "journal":"Clinical Pharmacology & Therapeutics",
    "publication_year":2025,
    "create_date":"2025-01-15",
    "pmcid":"",
    "doi":"10.7715\/m66d41crg4",
    "citation":"Brown W et al. Clinical Pharmacology & Therapeutics. 2025;128(9):442-441.",
    "product_inn":"Losartan",
    "product_id":15,
    "category":"relevant_safety_info",
    "adverse_events":[
      "Myalgia",
      "Gastrointestinal disturbances",
      "Elevated liver enzymes"
    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":true,
    "justification":"Long-term safety data from large cohort useful for periodic safety update reports"
  },
  {
    "id":63,
    "pmid":40691336,
    "title":"Long-term Cardiovascular Outcomes with Doxorubicin Therapy: 5-Year Follow-up Data",
    "abstract":"We present 5-year follow-up data from a cohort of 500 patients treated with Doxorubicin for cardiovascular disease prevention. The study assessed major adverse cardiovascular events (MACE), including myocardial infarction, stroke, and cardiovascular death. MACE occurred in 8.5% of patients. Common adverse effects included myalgia (15%), gastrointestinal disturbances (10%), and elevated liver enzymes (3%). The benefit-risk profile remained favorable throughout the follow-up period.",
    "authors":"Martinez L; Jones L; Garcia J; Martinez M",
    "first_author":"Martinez L",
    "journal":"BMC Pharmacology and Toxicology",
    "publication_year":2025,
    "create_date":"2025-03-14",
    "pmcid":"PMC2155555",
    "doi":"10.1102\/ku7mdd0e6a",
    "citation":"Martinez L et al. BMC Pharmacology and Toxicology. 2025;130(6):546-865.",
    "product_inn":"Doxorubicin",
    "product_id":10,
    "category":"relevant_safety_info",
    "adverse_events":[
      "Myalgia",
      "Gastrointestinal disturbances",
      "Elevated liver enzymes"
    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":true,
    "justification":"Long-term safety data from large cohort useful for periodic safety update reports"
  },
  {
    "id":64,
    "pmid":40314584,
    "title":"Comparative Safety Analysis of Metformin vs Alternative Therapies in Elderly Patients",
    "abstract":"This comparative study analyzed safety outcomes of Metformin versus alternative therapies in 300 elderly patients (age >65 years). The primary endpoint was incidence of adverse drug reactions. Metformin showed a favorable safety profile with lower rates of serious adverse events (4.2% vs 7.8%, p=0.03). Common adverse reactions included mild gastrointestinal symptoms and dizziness. The study supports the use of Metformin in elderly populations with appropriate monitoring.",
    "authors":"Brown E; Garcia R; Williams S; Williams M; Miller J",
    "first_author":"Brown E",
    "journal":"British Journal of Clinical Pharmacology",
    "publication_year":2024,
    "create_date":"2024-07-25",
    "pmcid":"PMC2921069",
    "doi":"10.3401\/st4gdebqzi",
    "citation":"Brown E et al. British Journal of Clinical Pharmacology. 2024;59(4):696-327.",
    "product_inn":"Metformin",
    "product_id":2,
    "category":"relevant_safety_info",
    "adverse_events":[
      "Gastrointestinal symptoms",
      "Dizziness"
    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":true,
    "justification":"Comparative safety data in special population (elderly) relevant for risk management activities"
  },
  {
    "id":65,
    "pmid":40801403,
    "title":"Comparative Safety Analysis of Atorvastatin vs Alternative Therapies in Elderly Patients",
    "abstract":"This comparative study analyzed safety outcomes of Atorvastatin versus alternative therapies in 300 elderly patients (age >65 years). The primary endpoint was incidence of adverse drug reactions. Atorvastatin showed a favorable safety profile with lower rates of serious adverse events (4.2% vs 7.8%, p=0.03). Common adverse reactions included mild gastrointestinal symptoms and dizziness. The study supports the use of Atorvastatin in elderly populations with appropriate monitoring.",
    "authors":"Jones E; Garcia L; Jones S",
    "first_author":"Jones E",
    "journal":"BMC Pharmacology and Toxicology",
    "publication_year":2024,
    "create_date":"2024-08-26",
    "pmcid":"",
    "doi":"10.8679\/pwbe2x01qd",
    "citation":"Jones E et al. BMC Pharmacology and Toxicology. 2024;104(1):885-591.",
    "product_inn":"Atorvastatin",
    "product_id":14,
    "category":"relevant_safety_info",
    "adverse_events":[
      "Gastrointestinal symptoms",
      "Dizziness"
    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":true,
    "justification":"Comparative safety data in special population (elderly) relevant for risk management activities"
  },
  {
    "id":66,
    "pmid":40399461,
    "title":"Long-term Cardiovascular Outcomes with Cisplatin Therapy: 5-Year Follow-up Data",
    "abstract":"We present 5-year follow-up data from a cohort of 500 patients treated with Cisplatin for cardiovascular disease prevention. The study assessed major adverse cardiovascular events (MACE), including myocardial infarction, stroke, and cardiovascular death. MACE occurred in 8.5% of patients. Common adverse effects included myalgia (15%), gastrointestinal disturbances (10%), and elevated liver enzymes (3%). The benefit-risk profile remained favorable throughout the follow-up period.",
    "authors":"Jones M; Williams L; Brown S; Williams E; Garcia S",
    "first_author":"Jones M",
    "journal":"BMC Pharmacology and Toxicology",
    "publication_year":2024,
    "create_date":"2024-06-09",
    "pmcid":"PMC1606551",
    "doi":"10.5812\/b2t5b007hj",
    "citation":"Jones M et al. BMC Pharmacology and Toxicology. 2024;44(5):974-825.",
    "product_inn":"Cisplatin",
    "product_id":8,
    "category":"relevant_safety_info",
    "adverse_events":[
      "Myalgia",
      "Gastrointestinal disturbances",
      "Elevated liver enzymes"
    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":true,
    "justification":"Long-term safety data from large cohort useful for periodic safety update reports"
  },
  {
    "id":67,
    "pmid":40800100,
    "title":"Comparative Safety Analysis of Atorvastatin vs Alternative Therapies in Elderly Patients",
    "abstract":"This comparative study analyzed safety outcomes of Atorvastatin versus alternative therapies in 300 elderly patients (age >65 years). The primary endpoint was incidence of adverse drug reactions. Atorvastatin showed a favorable safety profile with lower rates of serious adverse events (4.2% vs 7.8%, p=0.03). Common adverse reactions included mild gastrointestinal symptoms and dizziness. The study supports the use of Atorvastatin in elderly populations with appropriate monitoring.",
    "authors":"Johnson R; Smith M; Rodriguez W; Johnson M; Williams W; Smith J",
    "first_author":"Johnson R",
    "journal":"Clinical Pharmacology & Therapeutics",
    "publication_year":2024,
    "create_date":"2024-10-26",
    "pmcid":"PMC3745201",
    "doi":"10.7479\/ica89o261c",
    "citation":"Johnson R et al. Clinical Pharmacology & Therapeutics. 2024;66(3):857-862.",
    "product_inn":"Atorvastatin",
    "product_id":14,
    "category":"relevant_safety_info",
    "adverse_events":[
      "Gastrointestinal symptoms",
      "Dizziness"
    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":true,
    "justification":"Comparative safety data in special population (elderly) relevant for risk management activities"
  },
  {
    "id":68,
    "pmid":40499569,
    "title":"Comparative Safety Analysis of Cisplatin vs Alternative Therapies in Elderly Patients",
    "abstract":"This comparative study analyzed safety outcomes of Cisplatin versus alternative therapies in 300 elderly patients (age >65 years). The primary endpoint was incidence of adverse drug reactions. Cisplatin showed a favorable safety profile with lower rates of serious adverse events (4.2% vs 7.8%, p=0.03). Common adverse reactions included mild gastrointestinal symptoms and dizziness. The study supports the use of Cisplatin in elderly populations with appropriate monitoring.",
    "authors":"Miller W; Rodriguez R; Martinez W; Garcia M",
    "first_author":"Miller W",
    "journal":"Clinical Pharmacology & Therapeutics",
    "publication_year":2024,
    "create_date":"2024-12-16",
    "pmcid":"",
    "doi":"10.8967\/wbmjxouwo1",
    "citation":"Miller W et al. Clinical Pharmacology & Therapeutics. 2024;100(5):103-558.",
    "product_inn":"Cisplatin",
    "product_id":8,
    "category":"relevant_safety_info",
    "adverse_events":[
      "Gastrointestinal symptoms",
      "Dizziness"
    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":true,
    "justification":"Comparative safety data in special population (elderly) relevant for risk management activities"
  },
  {
    "id":69,
    "pmid":40810867,
    "title":"Comparative Safety Analysis of Metronidazole vs Alternative Therapies in Elderly Patients",
    "abstract":"This comparative study analyzed safety outcomes of Metronidazole versus alternative therapies in 300 elderly patients (age >65 years). The primary endpoint was incidence of adverse drug reactions. Metronidazole showed a favorable safety profile with lower rates of serious adverse events (4.2% vs 7.8%, p=0.03). Common adverse reactions included mild gastrointestinal symptoms and dizziness. The study supports the use of Metronidazole in elderly populations with appropriate monitoring.",
    "authors":"Smith R; Martinez M; Williams E; Johnson M; Martinez M",
    "first_author":"Smith R",
    "journal":"American Journal of Medicine",
    "publication_year":2024,
    "create_date":"2024-12-02",
    "pmcid":"",
    "doi":"10.2678\/h7usvoy62w",
    "citation":"Smith R et al. American Journal of Medicine. 2024;89(8):862-509.",
    "product_inn":"Metronidazole",
    "product_id":9,
    "category":"relevant_safety_info",
    "adverse_events":[
      "Gastrointestinal symptoms",
      "Dizziness"
    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":true,
    "justification":"Comparative safety data in special population (elderly) relevant for risk management activities"
  },
  {
    "id":70,
    "pmid":40464072,
    "title":"Efficacy and Safety of Cisatracurium in Treatment of Refractory Hypertension: A Retrospective Study",
    "abstract":"This retrospective study evaluated the efficacy and safety of Cisatracurium in 150 patients with refractory hypertension over a 12-month period. The study was conducted at five medical centers. Mean blood pressure reduction was 18\/12 mmHg. Adverse events were mild and included dizziness (12%), headache (8%), and fatigue (5%). No serious adverse events were reported. Cisatracurium demonstrated good tolerability and efficacy in this patient population.",
    "authors":"Johnson D; Smith S",
    "first_author":"Johnson D",
    "journal":"Clinical Pharmacology & Therapeutics",
    "publication_year":2024,
    "create_date":"2024-07-21",
    "pmcid":"PMC1571031",
    "doi":"10.6299\/9jk2qmo3d7",
    "citation":"Johnson D et al. Clinical Pharmacology & Therapeutics. 2024;15(6):367-397.",
    "product_inn":"Cisatracurium",
    "product_id":6,
    "category":"relevant_safety_info",
    "adverse_events":[
      "Dizziness",
      "Headache",
      "Fatigue"
    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":true,
    "justification":"Population study with safety and efficacy data useful for aggregate reporting and signal detection"
  },
  {
    "id":71,
    "pmid":40069836,
    "title":"Efficacy and Safety of Levothyroxine in Treatment of Refractory Hypertension: A Retrospective Study",
    "abstract":"This retrospective study evaluated the efficacy and safety of Levothyroxine in 150 patients with refractory hypertension over a 12-month period. The study was conducted at five medical centers. Mean blood pressure reduction was 18\/12 mmHg. Adverse events were mild and included dizziness (12%), headache (8%), and fatigue (5%). No serious adverse events were reported. Levothyroxine demonstrated good tolerability and efficacy in this patient population.",
    "authors":"Smith S; Jones W",
    "first_author":"Smith S",
    "journal":"British Journal of Clinical Pharmacology",
    "publication_year":2025,
    "create_date":"2025-10-20",
    "pmcid":"PMC7825874",
    "doi":"10.2259\/2glnry25e5",
    "citation":"Smith S et al. British Journal of Clinical Pharmacology. 2025;135(7):663-614.",
    "product_inn":"Levothyroxine",
    "product_id":13,
    "category":"relevant_safety_info",
    "adverse_events":[
      "Dizziness",
      "Headache",
      "Fatigue"
    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":true,
    "justification":"Population study with safety and efficacy data useful for aggregate reporting and signal detection"
  },
  {
    "id":72,
    "pmid":40901122,
    "title":"Efficacy and Safety of Warfarin in Treatment of Refractory Hypertension: A Retrospective Study",
    "abstract":"This retrospective study evaluated the efficacy and safety of Warfarin in 150 patients with refractory hypertension over a 12-month period. The study was conducted at five medical centers. Mean blood pressure reduction was 18\/12 mmHg. Adverse events were mild and included dizziness (12%), headache (8%), and fatigue (5%). No serious adverse events were reported. Warfarin demonstrated good tolerability and efficacy in this patient population.",
    "authors":"Smith E; Miller R; Jones J; Miller R; Rodriguez J; Miller M",
    "first_author":"Smith E",
    "journal":"Clinical Pharmacology & Therapeutics",
    "publication_year":2024,
    "create_date":"2024-02-15",
    "pmcid":"",
    "doi":"10.1934\/y56hj1y8cg",
    "citation":"Smith E et al. Clinical Pharmacology & Therapeutics. 2024;86(7):862-585.",
    "product_inn":"Warfarin",
    "product_id":11,
    "category":"relevant_safety_info",
    "adverse_events":[
      "Dizziness",
      "Headache",
      "Fatigue"
    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":true,
    "justification":"Population study with safety and efficacy data useful for aggregate reporting and signal detection"
  },
  {
    "id":73,
    "pmid":40581901,
    "title":"Long-term Cardiovascular Outcomes with Lisinopril Therapy: 5-Year Follow-up Data",
    "abstract":"We present 5-year follow-up data from a cohort of 500 patients treated with Lisinopril for cardiovascular disease prevention. The study assessed major adverse cardiovascular events (MACE), including myocardial infarction, stroke, and cardiovascular death. MACE occurred in 8.5% of patients. Common adverse effects included myalgia (15%), gastrointestinal disturbances (10%), and elevated liver enzymes (3%). The benefit-risk profile remained favorable throughout the follow-up period.",
    "authors":"Martinez L; Jones R; Davis R; Brown W; Martinez R; Miller D",
    "first_author":"Martinez L",
    "journal":"American Journal of Medicine",
    "publication_year":2025,
    "create_date":"2025-09-04",
    "pmcid":"PMC2456811",
    "doi":"10.7497\/i9l0imqvw2",
    "citation":"Martinez L et al. American Journal of Medicine. 2025;75(4):522-659.",
    "product_inn":"Lisinopril",
    "product_id":3,
    "category":"relevant_safety_info",
    "adverse_events":[
      "Myalgia",
      "Gastrointestinal disturbances",
      "Elevated liver enzymes"
    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":true,
    "justification":"Long-term safety data from large cohort useful for periodic safety update reports"
  },
  {
    "id":74,
    "pmid":40970293,
    "title":"Comparative Safety Analysis of Methylprednisolone vs Alternative Therapies in Elderly Patients",
    "abstract":"This comparative study analyzed safety outcomes of Methylprednisolone versus alternative therapies in 300 elderly patients (age >65 years). The primary endpoint was incidence of adverse drug reactions. Methylprednisolone showed a favorable safety profile with lower rates of serious adverse events (4.2% vs 7.8%, p=0.03). Common adverse reactions included mild gastrointestinal symptoms and dizziness. The study supports the use of Methylprednisolone in elderly populations with appropriate monitoring.",
    "authors":"Brown S; Davis D; Smith S; Brown J; Williams J",
    "first_author":"Brown S",
    "journal":"Drug Safety",
    "publication_year":2025,
    "create_date":"2025-05-01",
    "pmcid":"",
    "doi":"10.6079\/iekgdk5te1",
    "citation":"Brown S et al. Drug Safety. 2025;23(9):533-616.",
    "product_inn":"Methylprednisolone",
    "product_id":7,
    "category":"relevant_safety_info",
    "adverse_events":[
      "Gastrointestinal symptoms",
      "Dizziness"
    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":true,
    "justification":"Comparative safety data in special population (elderly) relevant for risk management activities"
  },
  {
    "id":75,
    "pmid":40910664,
    "title":"Comparative Safety Analysis of Metformin vs Alternative Therapies in Elderly Patients",
    "abstract":"This comparative study analyzed safety outcomes of Metformin versus alternative therapies in 300 elderly patients (age >65 years). The primary endpoint was incidence of adverse drug reactions. Metformin showed a favorable safety profile with lower rates of serious adverse events (4.2% vs 7.8%, p=0.03). Common adverse reactions included mild gastrointestinal symptoms and dizziness. The study supports the use of Metformin in elderly populations with appropriate monitoring.",
    "authors":"Jones J; Smith D; Brown R; Johnson J; Rodriguez D",
    "first_author":"Jones J",
    "journal":"European Journal of Clinical Pharmacology",
    "publication_year":2024,
    "create_date":"2024-09-25",
    "pmcid":"PMC7022621",
    "doi":"10.7205\/8y69j83xsw",
    "citation":"Jones J et al. European Journal of Clinical Pharmacology. 2024;145(11):900-229.",
    "product_inn":"Metformin",
    "product_id":2,
    "category":"relevant_safety_info",
    "adverse_events":[
      "Gastrointestinal symptoms",
      "Dizziness"
    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":true,
    "justification":"Comparative safety data in special population (elderly) relevant for risk management activities"
  },
  {
    "id":76,
    "pmid":40693145,
    "title":"Survey of Patient Satisfaction with Cisatracurium Therapy",
    "abstract":"A cross-sectional survey assessed patient satisfaction with Cisatracurium therapy among 200 outpatients. A validated questionnaire measured treatment satisfaction, quality of life, and adherence. Overall satisfaction score was 7.8\/10. Factors associated with higher satisfaction included fewer daily doses and perceived efficacy. Patient education and shared decision-making improved adherence rates. These findings can inform strategies to optimize patient experience with Cisatracurium therapy.",
    "authors":"Williams M; Johnson W; Johnson E; Williams J; Martinez J",
    "first_author":"Williams M",
    "journal":"BMC Pharmacology and Toxicology",
    "publication_year":2024,
    "create_date":"2024-10-09",
    "pmcid":"PMC1614371",
    "doi":"10.3663\/jd4ipp0wxo",
    "citation":"Williams M et al. BMC Pharmacology and Toxicology. 2024;37(7):706-543.",
    "product_inn":"Cisatracurium",
    "product_id":6,
    "category":"irrelevant",
    "adverse_events":[

    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":false,
    "justification":"Patient satisfaction survey - no specific adverse event or safety data"
  },
  {
    "id":77,
    "pmid":40045105,
    "title":"Molecular Mechanisms of Insulin Glargine Action in Cell Culture Models",
    "abstract":"This study investigated the molecular mechanisms of Insulin Glargine using HeLa cell culture models. We examined the effects on cell proliferation, apoptosis pathways, and gene expression profiles. Insulin Glargine demonstrated dose-dependent cytotoxicity with IC50 of 2.5 \u03bcM. Western blot analysis revealed activation of caspase-3 and PARP cleavage. Gene expression analysis identified 150 differentially expressed genes. These findings provide insights into the cellular mechanisms of Insulin Glargine action.",
    "authors":"Martinez J; Johnson R; Johnson D",
    "first_author":"Martinez J",
    "journal":"BMC Pharmacology and Toxicology",
    "publication_year":2024,
    "create_date":"2024-03-11",
    "pmcid":"PMC1759666",
    "doi":"10.5728\/50dmuv4cpr",
    "citation":"Martinez J et al. BMC Pharmacology and Toxicology. 2024;59(10):334-868.",
    "product_inn":"Insulin Glargine",
    "product_id":12,
    "category":"irrelevant",
    "adverse_events":[

    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":false,
    "justification":"Laboratory study using cell culture models - no human safety data"
  },
  {
    "id":78,
    "pmid":40368615,
    "title":"Cost-Effectiveness Analysis of Atorvastatin for Treatment of Chronic Disease",
    "abstract":"This economic evaluation assessed the cost-effectiveness of Atorvastatin compared to standard therapy for chronic disease management. A Markov model was constructed using published efficacy data and local cost data. The incremental cost-effectiveness ratio (ICER) was calculated. Atorvastatin demonstrated an ICER of $45,000 per quality-adjusted life year (QALY). Sensitivity analyses confirmed robustness of results. Atorvastatin represents good value for money in this indication.",
    "authors":"Brown E; Smith W; Smith R; Davis M; Rodriguez S",
    "first_author":"Brown E",
    "journal":"Internal Medicine",
    "publication_year":2025,
    "create_date":"2025-07-15",
    "pmcid":"",
    "doi":"10.6025\/450d7ygrd4",
    "citation":"Brown E et al. Internal Medicine. 2025;16(7):705-407.",
    "product_inn":"Atorvastatin",
    "product_id":14,
    "category":"irrelevant",
    "adverse_events":[

    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":false,
    "justification":"Health economics study - no safety or clinical data relevant for pharmacovigilance"
  },
  {
    "id":79,
    "pmid":40633291,
    "title":"Survey of Patient Satisfaction with Insulin Glargine Therapy",
    "abstract":"A cross-sectional survey assessed patient satisfaction with Insulin Glargine therapy among 200 outpatients. A validated questionnaire measured treatment satisfaction, quality of life, and adherence. Overall satisfaction score was 7.8\/10. Factors associated with higher satisfaction included fewer daily doses and perceived efficacy. Patient education and shared decision-making improved adherence rates. These findings can inform strategies to optimize patient experience with Insulin Glargine therapy.",
    "authors":"Williams L; Martinez J; Garcia J",
    "first_author":"Williams L",
    "journal":"Pharmacotherapy",
    "publication_year":2025,
    "create_date":"2025-10-13",
    "pmcid":"PMC2808144",
    "doi":"10.8265\/dl9s5esx5k",
    "citation":"Williams L et al. Pharmacotherapy. 2025;53(2):566-122.",
    "product_inn":"Insulin Glargine",
    "product_id":12,
    "category":"irrelevant",
    "adverse_events":[

    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":false,
    "justification":"Patient satisfaction survey - no specific adverse event or safety data"
  },
  {
    "id":80,
    "pmid":40372151,
    "title":"Environmental Impact Assessment of Lisinopril Manufacturing Processes",
    "abstract":"This study evaluated the environmental impact of Lisinopril manufacturing, including waste generation, water consumption, and carbon emissions. Life cycle assessment methodology was applied. The manufacturing process generated 2.5 kg CO2 equivalent per gram of active pharmaceutical ingredient. Recommendations for reducing environmental footprint include solvent recycling and energy efficiency improvements. Sustainable manufacturing practices are essential for pharmaceutical industry.",
    "authors":"Davis L; Rodriguez M; Smith J; Williams M; Miller S; Johnson S",
    "first_author":"Davis L",
    "journal":"Pharmacotherapy",
    "publication_year":2025,
    "create_date":"2025-08-18",
    "pmcid":"PMC4858875",
    "doi":"10.2628\/od3z8bkt2m",
    "citation":"Davis L et al. Pharmacotherapy. 2025;73(8):448-360.",
    "product_inn":"Lisinopril",
    "product_id":3,
    "category":"irrelevant",
    "adverse_events":[

    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":false,
    "justification":"Environmental study - not related to drug safety or adverse events"
  },
  {
    "id":81,
    "pmid":40485055,
    "title":"Survey of Patient Satisfaction with Warfarin Therapy",
    "abstract":"A cross-sectional survey assessed patient satisfaction with Warfarin therapy among 200 outpatients. A validated questionnaire measured treatment satisfaction, quality of life, and adherence. Overall satisfaction score was 7.8\/10. Factors associated with higher satisfaction included fewer daily doses and perceived efficacy. Patient education and shared decision-making improved adherence rates. These findings can inform strategies to optimize patient experience with Warfarin therapy.",
    "authors":"Smith R; Smith M",
    "first_author":"Smith R",
    "journal":"Clinical Pharmacology & Therapeutics",
    "publication_year":2025,
    "create_date":"2025-06-08",
    "pmcid":"",
    "doi":"10.7516\/27xnnzj7hs",
    "citation":"Smith R et al. Clinical Pharmacology & Therapeutics. 2025;44(1):874-286.",
    "product_inn":"Warfarin",
    "product_id":11,
    "category":"irrelevant",
    "adverse_events":[

    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":false,
    "justification":"Patient satisfaction survey - no specific adverse event or safety data"
  },
  {
    "id":82,
    "pmid":40337532,
    "title":"Survey of Patient Satisfaction with Doxorubicin Therapy",
    "abstract":"A cross-sectional survey assessed patient satisfaction with Doxorubicin therapy among 200 outpatients. A validated questionnaire measured treatment satisfaction, quality of life, and adherence. Overall satisfaction score was 7.8\/10. Factors associated with higher satisfaction included fewer daily doses and perceived efficacy. Patient education and shared decision-making improved adherence rates. These findings can inform strategies to optimize patient experience with Doxorubicin therapy.",
    "authors":"Williams S; Williams J; Davis L; Brown J",
    "first_author":"Williams S",
    "journal":"American Journal of Medicine",
    "publication_year":2025,
    "create_date":"2025-07-07",
    "pmcid":"",
    "doi":"10.9242\/szwm7m4ih2",
    "citation":"Williams S et al. American Journal of Medicine. 2025;31(11):437-620.",
    "product_inn":"Doxorubicin",
    "product_id":10,
    "category":"irrelevant",
    "adverse_events":[

    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":false,
    "justification":"Patient satisfaction survey - no specific adverse event or safety data"
  },
  {
    "id":83,
    "pmid":40163097,
    "title":"Cost-Effectiveness Analysis of Cisatracurium for Treatment of Chronic Disease",
    "abstract":"This economic evaluation assessed the cost-effectiveness of Cisatracurium compared to standard therapy for chronic disease management. A Markov model was constructed using published efficacy data and local cost data. The incremental cost-effectiveness ratio (ICER) was calculated. Cisatracurium demonstrated an ICER of $45,000 per quality-adjusted life year (QALY). Sensitivity analyses confirmed robustness of results. Cisatracurium represents good value for money in this indication.",
    "authors":"Williams D; Williams M; Williams D; Jones S",
    "first_author":"Williams D",
    "journal":"BMC Pharmacology and Toxicology",
    "publication_year":2025,
    "create_date":"2025-02-21",
    "pmcid":"PMC2815015",
    "doi":"10.8427\/gdmi6nhjak",
    "citation":"Williams D et al. BMC Pharmacology and Toxicology. 2025;64(11):432-394.",
    "product_inn":"Cisatracurium",
    "product_id":6,
    "category":"irrelevant",
    "adverse_events":[

    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":false,
    "justification":"Health economics study - no safety or clinical data relevant for pharmacovigilance"
  },
  {
    "id":84,
    "pmid":40031177,
    "title":"Molecular Mechanisms of Metformin Action in Cell Culture Models",
    "abstract":"This study investigated the molecular mechanisms of Metformin using HeLa cell culture models. We examined the effects on cell proliferation, apoptosis pathways, and gene expression profiles. Metformin demonstrated dose-dependent cytotoxicity with IC50 of 2.5 \u03bcM. Western blot analysis revealed activation of caspase-3 and PARP cleavage. Gene expression analysis identified 150 differentially expressed genes. These findings provide insights into the cellular mechanisms of Metformin action.",
    "authors":"Brown M; Miller L; Johnson J; Williams M; Jones R; Garcia J",
    "first_author":"Brown M",
    "journal":"American Journal of Medicine",
    "publication_year":2024,
    "create_date":"2024-10-03",
    "pmcid":"PMC1246903",
    "doi":"10.5531\/hzhp6oc9pq",
    "citation":"Brown M et al. American Journal of Medicine. 2024;35(2):952-980.",
    "product_inn":"Metformin",
    "product_id":2,
    "category":"irrelevant",
    "adverse_events":[

    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":false,
    "justification":"Laboratory study using cell culture models - no human safety data"
  },
  {
    "id":85,
    "pmid":40444547,
    "title":"Molecular Mechanisms of Metronidazole Action in Cell Culture Models",
    "abstract":"This study investigated the molecular mechanisms of Metronidazole using HeLa cell culture models. We examined the effects on cell proliferation, apoptosis pathways, and gene expression profiles. Metronidazole demonstrated dose-dependent cytotoxicity with IC50 of 2.5 \u03bcM. Western blot analysis revealed activation of caspase-3 and PARP cleavage. Gene expression analysis identified 150 differentially expressed genes. These findings provide insights into the cellular mechanisms of Metronidazole action.",
    "authors":"Williams J; Rodriguez M; Miller S; Smith M; Smith D",
    "first_author":"Williams J",
    "journal":"European Journal of Clinical Pharmacology",
    "publication_year":2024,
    "create_date":"2024-10-04",
    "pmcid":"PMC3674456",
    "doi":"10.1506\/ylcpaw1wee",
    "citation":"Williams J et al. European Journal of Clinical Pharmacology. 2024;48(8):456-176.",
    "product_inn":"Metronidazole",
    "product_id":9,
    "category":"irrelevant",
    "adverse_events":[

    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":false,
    "justification":"Laboratory study using cell culture models - no human safety data"
  },
  {
    "id":86,
    "pmid":40277263,
    "title":"Molecular Mechanisms of Insulin Glargine Action in Cell Culture Models",
    "abstract":"This study investigated the molecular mechanisms of Insulin Glargine using HeLa cell culture models. We examined the effects on cell proliferation, apoptosis pathways, and gene expression profiles. Insulin Glargine demonstrated dose-dependent cytotoxicity with IC50 of 2.5 \u03bcM. Western blot analysis revealed activation of caspase-3 and PARP cleavage. Gene expression analysis identified 150 differentially expressed genes. These findings provide insights into the cellular mechanisms of Insulin Glargine action.",
    "authors":"Smith M; Brown L; Martinez M",
    "first_author":"Smith M",
    "journal":"European Journal of Clinical Pharmacology",
    "publication_year":2025,
    "create_date":"2025-10-05",
    "pmcid":"PMC7249411",
    "doi":"10.4257\/l62s0nxdpg",
    "citation":"Smith M et al. European Journal of Clinical Pharmacology. 2025;64(6):660-418.",
    "product_inn":"Insulin Glargine",
    "product_id":12,
    "category":"irrelevant",
    "adverse_events":[

    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":false,
    "justification":"Laboratory study using cell culture models - no human safety data"
  },
  {
    "id":87,
    "pmid":40934030,
    "title":"Pharmacokinetic Study of Atorvastatin in Rat Models",
    "abstract":"The pharmacokinetic properties of Atorvastatin were evaluated in male Wistar rats (n=24). Animals received single doses of 10, 25, or 50 mg\/kg via oral gavage. Blood samples were collected at multiple time points over 24 hours. Plasma concentrations were measured using HPLC-MS\/MS. The mean Cmax, Tmax, and AUC values were determined. The elimination half-life was approximately 4.2 hours. These preclinical data support further development of Atorvastatin.",
    "authors":"Rodriguez R; Miller D; Williams S; Smith J; Johnson E; Johnson J",
    "first_author":"Rodriguez R",
    "journal":"American Journal of Medicine",
    "publication_year":2024,
    "create_date":"2024-08-08",
    "pmcid":"",
    "doi":"10.3500\/zoyvak5czo",
    "citation":"Rodriguez R et al. American Journal of Medicine. 2024;55(9):807-720.",
    "product_inn":"Atorvastatin",
    "product_id":14,
    "category":"irrelevant",
    "adverse_events":[

    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":false,
    "justification":"Animal study - preclinical pharmacokinetic data not relevant for human pharmacovigilance"
  },
  {
    "id":88,
    "pmid":40511690,
    "title":"Survey of Patient Satisfaction with Warfarin Therapy",
    "abstract":"A cross-sectional survey assessed patient satisfaction with Warfarin therapy among 200 outpatients. A validated questionnaire measured treatment satisfaction, quality of life, and adherence. Overall satisfaction score was 7.8\/10. Factors associated with higher satisfaction included fewer daily doses and perceived efficacy. Patient education and shared decision-making improved adherence rates. These findings can inform strategies to optimize patient experience with Warfarin therapy.",
    "authors":"Williams W; Jones R; Martinez W; Smith J",
    "first_author":"Williams W",
    "journal":"American Journal of Medicine",
    "publication_year":2024,
    "create_date":"2024-03-10",
    "pmcid":"",
    "doi":"10.3872\/udwdf97zqm",
    "citation":"Williams W et al. American Journal of Medicine. 2024;69(12):249-420.",
    "product_inn":"Warfarin",
    "product_id":11,
    "category":"irrelevant",
    "adverse_events":[

    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":false,
    "justification":"Patient satisfaction survey - no specific adverse event or safety data"
  },
  {
    "id":89,
    "pmid":40381040,
    "title":"Environmental Impact Assessment of Cisatracurium Manufacturing Processes",
    "abstract":"This study evaluated the environmental impact of Cisatracurium manufacturing, including waste generation, water consumption, and carbon emissions. Life cycle assessment methodology was applied. The manufacturing process generated 2.5 kg CO2 equivalent per gram of active pharmaceutical ingredient. Recommendations for reducing environmental footprint include solvent recycling and energy efficiency improvements. Sustainable manufacturing practices are essential for pharmaceutical industry.",
    "authors":"Martinez R; Davis S; Johnson R; Jones R; Miller E; Martinez R",
    "first_author":"Martinez R",
    "journal":"Drug Safety",
    "publication_year":2024,
    "create_date":"2024-10-07",
    "pmcid":"",
    "doi":"10.5035\/njude2auwg",
    "citation":"Martinez R et al. Drug Safety. 2024;142(12):236-356.",
    "product_inn":"Cisatracurium",
    "product_id":6,
    "category":"irrelevant",
    "adverse_events":[

    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":false,
    "justification":"Environmental study - not related to drug safety or adverse events"
  },
  {
    "id":90,
    "pmid":40726553,
    "title":"Survey of Patient Satisfaction with Metformin Therapy",
    "abstract":"A cross-sectional survey assessed patient satisfaction with Metformin therapy among 200 outpatients. A validated questionnaire measured treatment satisfaction, quality of life, and adherence. Overall satisfaction score was 7.8\/10. Factors associated with higher satisfaction included fewer daily doses and perceived efficacy. Patient education and shared decision-making improved adherence rates. These findings can inform strategies to optimize patient experience with Metformin therapy.",
    "authors":"Williams M; Martinez E; Brown L",
    "first_author":"Williams M",
    "journal":"Journal of Medical Case Reports",
    "publication_year":2025,
    "create_date":"2025-05-13",
    "pmcid":"PMC5260076",
    "doi":"10.2575\/ifjid31och",
    "citation":"Williams M et al. Journal of Medical Case Reports. 2025;126(12):247-790.",
    "product_inn":"Metformin",
    "product_id":2,
    "category":"irrelevant",
    "adverse_events":[

    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":false,
    "justification":"Patient satisfaction survey - no specific adverse event or safety data"
  },
  {
    "id":91,
    "pmid":40596630,
    "title":"Survey of Patient Satisfaction with Cisatracurium Therapy",
    "abstract":"A cross-sectional survey assessed patient satisfaction with Cisatracurium therapy among 200 outpatients. A validated questionnaire measured treatment satisfaction, quality of life, and adherence. Overall satisfaction score was 7.8\/10. Factors associated with higher satisfaction included fewer daily doses and perceived efficacy. Patient education and shared decision-making improved adherence rates. These findings can inform strategies to optimize patient experience with Cisatracurium therapy.",
    "authors":"Martinez M; Williams S",
    "first_author":"Martinez M",
    "journal":"European Journal of Clinical Pharmacology",
    "publication_year":2024,
    "create_date":"2024-09-26",
    "pmcid":"PMC8798834",
    "doi":"10.8505\/5ph6834h9o",
    "citation":"Martinez M et al. European Journal of Clinical Pharmacology. 2024;80(2):168-270.",
    "product_inn":"Cisatracurium",
    "product_id":6,
    "category":"irrelevant",
    "adverse_events":[

    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":false,
    "justification":"Patient satisfaction survey - no specific adverse event or safety data"
  },
  {
    "id":92,
    "pmid":40055622,
    "title":"Molecular Mechanisms of Cisatracurium Action in Cell Culture Models",
    "abstract":"This study investigated the molecular mechanisms of Cisatracurium using HeLa cell culture models. We examined the effects on cell proliferation, apoptosis pathways, and gene expression profiles. Cisatracurium demonstrated dose-dependent cytotoxicity with IC50 of 2.5 \u03bcM. Western blot analysis revealed activation of caspase-3 and PARP cleavage. Gene expression analysis identified 150 differentially expressed genes. These findings provide insights into the cellular mechanisms of Cisatracurium action.",
    "authors":"Martinez J; Garcia J; Martinez M; Garcia S; Brown D",
    "first_author":"Martinez J",
    "journal":"Pharmacotherapy",
    "publication_year":2024,
    "create_date":"2024-08-01",
    "pmcid":"",
    "doi":"10.7987\/id4cvefzc1",
    "citation":"Martinez J et al. Pharmacotherapy. 2024;85(2):519-765.",
    "product_inn":"Cisatracurium",
    "product_id":6,
    "category":"irrelevant",
    "adverse_events":[

    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":false,
    "justification":"Laboratory study using cell culture models - no human safety data"
  },
  {
    "id":93,
    "pmid":40983715,
    "title":"Molecular Mechanisms of Atorvastatin Action in Cell Culture Models",
    "abstract":"This study investigated the molecular mechanisms of Atorvastatin using HeLa cell culture models. We examined the effects on cell proliferation, apoptosis pathways, and gene expression profiles. Atorvastatin demonstrated dose-dependent cytotoxicity with IC50 of 2.5 \u03bcM. Western blot analysis revealed activation of caspase-3 and PARP cleavage. Gene expression analysis identified 150 differentially expressed genes. These findings provide insights into the cellular mechanisms of Atorvastatin action.",
    "authors":"Johnson M; Davis R; Davis D; Garcia M; Williams M; Garcia S",
    "first_author":"Johnson M",
    "journal":"Journal of Clinical Pharmacology",
    "publication_year":2025,
    "create_date":"2025-06-17",
    "pmcid":"",
    "doi":"10.2762\/l3ihkq8b3a",
    "citation":"Johnson M et al. Journal of Clinical Pharmacology. 2025;52(8):809-156.",
    "product_inn":"Atorvastatin",
    "product_id":14,
    "category":"irrelevant",
    "adverse_events":[

    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":false,
    "justification":"Laboratory study using cell culture models - no human safety data"
  },
  {
    "id":94,
    "pmid":40070515,
    "title":"Cost-Effectiveness Analysis of Warfarin for Treatment of Chronic Disease",
    "abstract":"This economic evaluation assessed the cost-effectiveness of Warfarin compared to standard therapy for chronic disease management. A Markov model was constructed using published efficacy data and local cost data. The incremental cost-effectiveness ratio (ICER) was calculated. Warfarin demonstrated an ICER of $45,000 per quality-adjusted life year (QALY). Sensitivity analyses confirmed robustness of results. Warfarin represents good value for money in this indication.",
    "authors":"Brown M; Brown S; Davis J; Smith J; Jones M",
    "first_author":"Brown M",
    "journal":"Internal Medicine",
    "publication_year":2025,
    "create_date":"2025-09-14",
    "pmcid":"",
    "doi":"10.9725\/0w3s3cv72r",
    "citation":"Brown M et al. Internal Medicine. 2025;74(12):473-938.",
    "product_inn":"Warfarin",
    "product_id":11,
    "category":"irrelevant",
    "adverse_events":[

    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":false,
    "justification":"Health economics study - no safety or clinical data relevant for pharmacovigilance"
  },
  {
    "id":95,
    "pmid":40116745,
    "title":"Cost-Effectiveness Analysis of Simvastatin for Treatment of Chronic Disease",
    "abstract":"This economic evaluation assessed the cost-effectiveness of Simvastatin compared to standard therapy for chronic disease management. A Markov model was constructed using published efficacy data and local cost data. The incremental cost-effectiveness ratio (ICER) was calculated. Simvastatin demonstrated an ICER of $45,000 per quality-adjusted life year (QALY). Sensitivity analyses confirmed robustness of results. Simvastatin represents good value for money in this indication.",
    "authors":"Rodriguez L; Williams S; Davis R; Rodriguez L; Brown J; Brown M",
    "first_author":"Rodriguez L",
    "journal":"Pharmacotherapy",
    "publication_year":2024,
    "create_date":"2024-07-28",
    "pmcid":"",
    "doi":"10.5675\/d9qk8fqvcr",
    "citation":"Rodriguez L et al. Pharmacotherapy. 2024;100(4):804-136.",
    "product_inn":"Simvastatin",
    "product_id":5,
    "category":"irrelevant",
    "adverse_events":[

    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":false,
    "justification":"Health economics study - no safety or clinical data relevant for pharmacovigilance"
  },
  {
    "id":96,
    "pmid":40598650,
    "title":"Pharmacokinetic Study of Metformin in Rat Models",
    "abstract":"The pharmacokinetic properties of Metformin were evaluated in male Wistar rats (n=24). Animals received single doses of 10, 25, or 50 mg\/kg via oral gavage. Blood samples were collected at multiple time points over 24 hours. Plasma concentrations were measured using HPLC-MS\/MS. The mean Cmax, Tmax, and AUC values were determined. The elimination half-life was approximately 4.2 hours. These preclinical data support further development of Metformin.",
    "authors":"Williams M; Johnson E; Miller J; Jones D; Williams D",
    "first_author":"Williams M",
    "journal":"Drug Safety",
    "publication_year":2025,
    "create_date":"2025-05-03",
    "pmcid":"PMC7716927",
    "doi":"10.2323\/0x8y9m6dr9",
    "citation":"Williams M et al. Drug Safety. 2025;89(5):711-413.",
    "product_inn":"Metformin",
    "product_id":2,
    "category":"irrelevant",
    "adverse_events":[

    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":false,
    "justification":"Animal study - preclinical pharmacokinetic data not relevant for human pharmacovigilance"
  },
  {
    "id":97,
    "pmid":40566966,
    "title":"Cost-Effectiveness Analysis of Cisatracurium for Treatment of Chronic Disease",
    "abstract":"This economic evaluation assessed the cost-effectiveness of Cisatracurium compared to standard therapy for chronic disease management. A Markov model was constructed using published efficacy data and local cost data. The incremental cost-effectiveness ratio (ICER) was calculated. Cisatracurium demonstrated an ICER of $45,000 per quality-adjusted life year (QALY). Sensitivity analyses confirmed robustness of results. Cisatracurium represents good value for money in this indication.",
    "authors":"Williams L; Smith S; Miller M",
    "first_author":"Williams L",
    "journal":"Journal of Medical Case Reports",
    "publication_year":2025,
    "create_date":"2025-09-13",
    "pmcid":"",
    "doi":"10.1375\/2bcu8u4y16",
    "citation":"Williams L et al. Journal of Medical Case Reports. 2025;142(7):100-410.",
    "product_inn":"Cisatracurium",
    "product_id":6,
    "category":"irrelevant",
    "adverse_events":[

    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":false,
    "justification":"Health economics study - no safety or clinical data relevant for pharmacovigilance"
  },
  {
    "id":98,
    "pmid":40789756,
    "title":"Molecular Mechanisms of Methylprednisolone Action in Cell Culture Models",
    "abstract":"This study investigated the molecular mechanisms of Methylprednisolone using HeLa cell culture models. We examined the effects on cell proliferation, apoptosis pathways, and gene expression profiles. Methylprednisolone demonstrated dose-dependent cytotoxicity with IC50 of 2.5 \u03bcM. Western blot analysis revealed activation of caspase-3 and PARP cleavage. Gene expression analysis identified 150 differentially expressed genes. These findings provide insights into the cellular mechanisms of Methylprednisolone action.",
    "authors":"Rodriguez J; Smith M; Davis J",
    "first_author":"Rodriguez J",
    "journal":"European Journal of Clinical Pharmacology",
    "publication_year":2025,
    "create_date":"2025-01-28",
    "pmcid":"",
    "doi":"10.4493\/ehtbsqg0e7",
    "citation":"Rodriguez J et al. European Journal of Clinical Pharmacology. 2025;121(9):865-620.",
    "product_inn":"Methylprednisolone",
    "product_id":7,
    "category":"irrelevant",
    "adverse_events":[

    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":false,
    "justification":"Laboratory study using cell culture models - no human safety data"
  },
  {
    "id":99,
    "pmid":40571073,
    "title":"Molecular Mechanisms of Simvastatin Action in Cell Culture Models",
    "abstract":"This study investigated the molecular mechanisms of Simvastatin using HeLa cell culture models. We examined the effects on cell proliferation, apoptosis pathways, and gene expression profiles. Simvastatin demonstrated dose-dependent cytotoxicity with IC50 of 2.5 \u03bcM. Western blot analysis revealed activation of caspase-3 and PARP cleavage. Gene expression analysis identified 150 differentially expressed genes. These findings provide insights into the cellular mechanisms of Simvastatin action.",
    "authors":"Jones M; Williams E; Smith J; Smith M; Smith W; Martinez E",
    "first_author":"Jones M",
    "journal":"Pharmacotherapy",
    "publication_year":2025,
    "create_date":"2025-12-16",
    "pmcid":"",
    "doi":"10.6288\/mhimt8pyzi",
    "citation":"Jones M et al. Pharmacotherapy. 2025;145(8):247-764.",
    "product_inn":"Simvastatin",
    "product_id":5,
    "category":"irrelevant",
    "adverse_events":[

    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":false,
    "justification":"Laboratory study using cell culture models - no human safety data"
  },
  {
    "id":100,
    "pmid":40433431,
    "title":"Pharmacokinetic Study of Omeprazole in Rat Models",
    "abstract":"The pharmacokinetic properties of Omeprazole were evaluated in male Wistar rats (n=24). Animals received single doses of 10, 25, or 50 mg\/kg via oral gavage. Blood samples were collected at multiple time points over 24 hours. Plasma concentrations were measured using HPLC-MS\/MS. The mean Cmax, Tmax, and AUC values were determined. The elimination half-life was approximately 4.2 hours. These preclinical data support further development of Omeprazole.",
    "authors":"Johnson W; Jones E; Brown S; Brown M; Miller M",
    "first_author":"Johnson W",
    "journal":"Internal Medicine",
    "publication_year":2025,
    "create_date":"2025-01-07",
    "pmcid":"PMC1177733",
    "doi":"10.6995\/mkp41c3yge",
    "citation":"Johnson W et al. Internal Medicine. 2025;37(1):437-911.",
    "product_inn":"Omeprazole",
    "product_id":4,
    "category":"irrelevant",
    "adverse_events":[

    ],
    "has_all_icsr_criteria":false,
    "ownership_excluded":null,
    "exclusion_reason":null,
    "is_relevant_safety_info":false,
    "justification":"Animal study - preclinical pharmacokinetic data not relevant for human pharmacovigilance"
  }
]